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ABSTRACT 
INTRODUCTION: Advances in genetic and genomic research have introduced new 
challenges in obtaining informed consent for research in low and middle-income settings. 
However, there are only few studies that have explored challenges in obtaining informed 
consent in genetic and genomic research in Africa and none in South Africa. To start filling 
this gap, we conducted an empirical study to investigate the efficacy of informed consent 
procedures for a genomic study on Rheumatic Heart Disease (RHDGen) at the University 
of Cape Town in South Africa. The main aim of the study was to understand the ethical 
challenges in obtaining informed consent in the RHDGen study. 
METHODS: We used a qualitative study methodology involving in-depth interviews and 
participant observations. Our research participants were RHDGen cases and controls as 
well as research staff involved in the recruitment of RHDGen research participants. In 
total, we conducted 32 in-depth interviews with RHDGen research participants, 2 in-depth 
interviews with research staff and 57 direct observations of the consent procedures of 
RHDGen research participants. The in-depth interviews were conducted in English, 
audio-recorded and transcribed verbatim. All the data were analysed using thematic 
content analysis. The study was conducted in 3 sites within Cape Town, South Africa, 
and these sites were the Groote Schuur Hospital in Observatory, the Vanguard 
Community Health Centre in Bonteheuwel and the Heideveld Community in the Cape 
Flats. 
RESULTS: Most healthy controls joined the RHDGen study in order to be screened for 
rheumatic heart disease (diagnostic misconception). Some patients thought the RHDGen 
study was part of routine clinical care (therapeutic misconception). Some research staff 
felt unsafe and insecure at one of the recruitment sites. A majority of RHD patients joined 
the RHDGen study in order to help future RHD patients (altruism). Some research 
participants were scared of giving blood. There was a potential breach of privacy and 
confidentiality for RHDGen controls recruited in the van. Some RHDGen research 
participants had trust in clinicians who were part of the RHDGen research team. Some 
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research participants had difficulty in understanding genetics, genomics, DNA and data 
sharing. Finally, research nurses had challenges in explaining genetics, genomics, DNA 
and data sharing to research participants. 
CONCLUSION: Ethical challenges that impacted on obtaining informed consent in the 
RHDGen study are complex. In this study, the challenges included diagnostic and 
therapeutic misconception, safety and insecurity, altruism, fear of giving blood, potential 
breach of privacy and confidentiality, trust and difficulty in understanding genetics, 
genomics, DNA and data sharing. 
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1 INTRODUCTION 
Recently, there has been an increase in genetic and genomic research in the world. Since 
the launch of the Human Genome Project (HGP) by the National Human Genome 
Research Institute of the National Institutes of Health and the US Department of Energy 
in the 1990s, there have been different research studies involving genetics and genomics. 
Researchers have been conducting both genetic and genomic studies in order to 
understand the contribution of both genetics and genomics to health and wellbeing. 
Genetic and genomic research studies raise slightly different ethical issues from 
biomedical research studies. While genetic research studies focus on certain genes or 
certain parts of the DNA that cause specific diseases such as Sickle Cell Disease and 
Huntington’s disease, in which case only that part of the DNA that causes the specific 
disease would be analysed, genomic research studies focus on the whole genome [1]. In 
other words, genetic research generates information about a specific disease or condition 
under study by analysing some aspect of the gene that causes the disease while genomic 
research provides us with genetic information for a multitude of diseases and traits, 
including finding out about predispositions to developing other conditions that may be 
completely unrelated to the disease being investigated in the original study.  
Of special interest are genomic epidemiological studies that attempt to understand 
genetic and environmental causes of complex diseases such as rheumatic heart disease, 
diabetes, cancer, asthma, malaria, HIV/AIDS and tuberculosis [1]. Such studies gather 
information about interactions of multiple genes across the whole genome, together with 
environmental factors in order to understand the causes of the complex diseases. They 
collect clinical, socio-demographic and genomic data of a large number of different 
populations and their findings could generate knowledge about the biology of conditions 
under study, including identifying molecular pathways previously unknown to be involved 
in the disease. Scientists hope that such knowledge could lead to the development of 
new interventions or therapies to treat or prevent such diseases. Since genomic 
epidemiological studies require large sample sizes, sometimes researchers use stored 
biological samples with the corresponding clinical and socio-demographic data in addition 
to newly collected samples from both cases and controls and other relevant data.  
13 
 
Two major recent consortia in genomic research in Africa have been the Malaria Genomic 
Epidemiology Network (MalariaGEN) and the Human, Health and Heredity in Africa 
(H3Africa). The MalariaGEN was a partnership of malaria researchers in over 20 
countries in Africa, Asia and Oceania supported by the Grand Challenges in Global Health 
Initiative [2]. The H3Africa is a consortium of African scientists funded by the Wellcome 
Trust and the US National Institutes of Health in partnership with the African Society for 
Human Genetics whose main aim is to foster genomic research expertise on the African 
continent with the goal of using genomic methods to address health inequities in both 
communicable and non-communicable diseases in Africa [3]. The main objective of the 
H3Africa consortium is to enhance the capacity of African researchers to conduct 
genomic research among African populations. Most H3Africa research grants are 
awarded directly to African institutions where principal investigators are based and this 
allows African scientists to develop and direct their independent research agendas in 
response to health priorities in their countries. The H3Africa consortium also encourages 
formation of intracontinental collaborations and development of specific infrastructural 
elements such as Africa-based bio-repositories and a pan-African bioinformatics network 
(H3ABio-Net). It also includes training programs aimed at retaining African scientists on 
the continent to help build a sustainable critical mass of African researchers [3]. Currently, 
there are 21 H3Africa funded projects, each of which involves collaboration in its own 
right. Under these projects, genomic research studies on conditions such as 
cardiovascular diseases, rheumatic heart disease and diabetes are being conducted [4]. 
1.1 A background of the Genomics of Rheumatic Heart Disease 
Network (RHDGen) Study 
The RHDGen Study is one of the genomic research projects funded by the Wellcome 
Trust under the H3Africa consortium. Rheumatic heart disease (RHD) is a chronic heart 
condition that is caused by rheumatic fever (RF). RF is caused by a bacterium called 
Streptococcus pyogenes that make some people have a sore throat. While some people 
get better from this infection, others develop rheumatic heart disease. However, the 
infection can be prevented from developing into rheumatic heart disease by taking 
antibiotics such as penicillin [5, 6 and 7]. Currently, RHD remains the most common 
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cardiovascular disease in young people under the age of 25 and it manifests itself with 
heart failure, stroke, infective endocarditis and pregnancy-related complications [8]. Right 
now, scientists do not understand why some people with the infection develop RHD while 
others do not develop the disease. Nevertheless, there is a belief that the reason why 
some people get better and others develop the RHD is to do with “genetics”. Therefore, 
the RHDGen study aims at understanding the genetics of RHD. The RHDGen study is 
recruiting 2500 adult patients with echocardiographically-confirmed RHD and it will 
compare them with 3500 normal people (healthy population-controls) from 8 sub-Saharan 
African countries in order to identify genetic factors of risk. The eight countries involved 
in the RHDGen network are Kenya, Mozambique, Namibia, Nigeria, South Africa, Sudan, 
Uganda and Zambia. This study on ethical challenges in obtaining informed consent in 
the RHDGen study was nested in the RHDGen study in South Africa specifically in the 
Western Cape where both RHD cases and controls are being recruited. 
2 LITERATURE REVIEW 
Ethical issues in both biomedical research and genomic research have received 
increasing attention. Both biomedical research and genomic research raise a host of 
ethical challenges, some of which are unique to Africa and its people while others are 
similar to ethical challenges raised elsewhere in the world [3]. The main focus of the 
ethical issues raised has been on the ethical implications of carrying out biomedical and 
genomic research in low socioeconomic settings. However, in all international ethics 
guidelines, principles and documents such as the Nuremberg Code, the Declaration of 
Helsinki, the Council for International Organizations of Medical Sciences (CIOMS), the 
US National Research Act, the Belmont Report, the Code of Federal Regulations (CFR), 
the World Health Organization (WHO) and the International Conference on 
Harmonization Guidelines for Good Clinical Practice (ICH-GCP), informed consent is 
described as paramount for the ethical conduct of research [9, 10, 11, 12, 13 and 14].  
The theory of informed consent originates from the ethical principle of autonomy or 
respect for persons and it is based on the principle that competent individuals are entitled 
to choose freely whether to participate in research or not [9, 10, 11 and 12]. In fact, the 
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CIOMS guideline number four defines informed consent as a decision to participate in 
research, taken by a competent individual who has received the necessary information; 
who has adequately understood the information; and who, after considering the 
information, has arrived at a decision without having been subjected to coercion, undue 
influence or inducement, or intimidation [11]. From this definition of informed consent, 
there are four main elements that are important in a research setting namely, (1) full 
disclosure of appropriate information about a research study to a potential research 
participant; (2) adequate understanding or comprehension of the disclosed information 
by the potential research participant; (3) legal and mental competence or capacity of the 
potential research participant to make a decision to participate; (4) and voluntary 
authorization or voluntariness of the potential research participant to join research with 
written documentation or an acceptable alternative.  
In order to obtain genuine informed consent, researchers are required to meet all the four 
elements stipulated in the above definition. This means any informed consent is said to 
be genuine if research participation is adequately informed and understood, and it is 
voluntarily given by a potential research participant who is competent to do so [2]. 
Obtaining genuine informed consent is considered as both an ethical obligation and a 
legal requirement for protection of the basic human rights of research participants. For 
example, the right to informed consent is a legal requirement in South Africa that is 
enshrined in the constitution and it is also a legal requirement in many countries in the 
world. The ethical obligation of respecting the autonomy of potential research participants 
is met by allowing them to make independent or voluntary decisions to participate in 
research free of coercion or undue influence and allowing them to withdraw from research 
participation voluntarily at any time without prejudice while the legal requirement is 
expressed in the signed consent form or document which is a contract between a 
researcher and a research participant. Of course, satisfaction of the legal requirement 
does not necessarily guarantee satisfying the ethical obligation and vice versa. This is so 
because potential research participants can sign informed consent forms without 
necessarily making autonomous decisions to participate in research or they can decide 
to participate in research without necessarily signing informed consent forms. Therefore, 
obtaining genuine informed consent in practice is difficult because even though the legal 
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requirements of informed consent may be met, the ethical requirements of informed 
consent may not necessarily have been achieved in practice [15]. Nevertheless, there is 
general consensus among researchers, scientists and bioethicists that acquiring genuine 
informed consent from research participants is a prerequisite for the conduct of an 
ethically sound study [16]. Despite general agreement on the above essential elements 
of an informed consent, there are many challenges to achieving genuine informed 
consent in practice [17] in both biomedical research and genomic research. Obtaining 
genuine informed consent for biomedical research and genomic research is very 
challenging regardless of whether the research is conducted in Africa or elsewhere in the 
world. 
2.1 Ethical challenges in obtaining informed consent in biomedical 
research 
Empirical research shows that obtaining genuine informed consent in biomedical 
research is difficult in practice in both developing and developed countries [3]. Based on 
various studies on informed consent conducted in both developing countries and 
developed countries which reported similar findings in both settings, Christine Pace and 
others as well as Amulya Mandava and others have concluded that there is no compelling 
evidence for claims that informed consent is worse in developing countries than in 
developed countries [18-19]. However, there are other studies that have reported that the 
challenges of getting genuine informed consent are greater in settings with low 
socioeconomic status than those with high socioeconomic status [15, 20, and 21]. There 
are various studies that have documented that there are many challenges in getting 
illiterate participants and participants with low socio-economic status to freely and 
voluntarily join biomedical research [22 – 34]. The conditions of poverty and illiteracy as 
well as the history of political oppression in low- and middle income countries make it 
difficult to obtain genuine informed consent from research participants in research 
practice because they all present numerous challenges to ensuring research participants’ 
understanding and voluntariness as well as the attainment of quality informed consent. 
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Language is one of the challenges in obtaining genuine informed consent. Language 
becomes a challenge especially in the disclosure of information to potential research 
participants and understanding of such information. This is the case because some 
languages lack certain words for scientific terms and many cultures cannot readily 
conceptualize pivotal biomedical and scientific concepts. For example, it is very 
challenging for researchers to explain to potential research participants the concepts of 
double-blinding, placebo, vaccine and randomization in a research setting [28 - 34]. Some 
languages lack precise translations for such scientific terminologies [35], and even in 
cases where researchers are able to translate scientific concepts into indigenous 
languages, the translations are usually made using universal language. The resulting 
translation may not be intelligible to prospective research participants who speak a more 
colloquial version of the language. 
Illiteracy among prospective research participants is another challenge in obtaining 
informed consent. It may affect both the transmission of research information to 
prospective research participants and its comprehension [35]. Although verbal 
communication is an alternative to providing information to illiterate research participants, 
it still poses a challenge between researchers and research participants who come from 
different ethnic/language groups. As such, illiteracy may result into low levels of 
understanding among prospective research participants. Related to this challenge is 
prospective research participants’ exposure to research or their scientific literacy. 
Researchers have difficulty to convey research aims and methods to prospective 
research participants who have not previously been exposed to scientific and research 
concepts [15, 36]. 
A third challenge in the transmission of information to prospective research participants 
is the power differential or level of trust between researchers and research participants 
[37]. In cases where researchers also provide health care to their prospective research 
participants, the research participants may feel obliged to participate in their medical 
doctors’ research because they trust them. They may also feel that they will not be 
attended to by the doctors if they refuse to participate in their research projects [37]. 
Various studies have also found that research participants who participate in their doctors’ 
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research projects have problems in understanding the differences between research and 
routine clinical care and that therapeutic misconception is very common especially among 
research participants in resource-poor settings [15 – 25]. Prospective research 
participants might not differentiate research from the routine care they receive from the 
same medical doctors who are also researchers and they may think that participation in 
the research projects is part of routine care. 
To overcome the above challenges, some researchers have suggested that scientific 
jargon and concepts can be adapted to local cultural norms, ideas and idioms [24, 34]. 
There have been suggestions that local analogies can be used to explain scientific 
concepts such as placebo and randomization. Researchers have also suggested the use 
of videos and pictures to explain scientific concepts to prospective research participants 
during the consent process [15, 34]. Others have proposed a variety of comprehension 
tests at the end of the consent process to verify research participants’ understanding. 
These can either be self-reported or administered by research staff [38 – 39]. These 
suggestions have been tried and tested in different research settings but they have 
proven not to be successful. Other researchers have suggested that community 
engagement activities should be conducted before implementation of research projects 
in order to enhance prospective research participants’ understanding and deal with any 
misconceptions prospective research participants might have about research before they 
are requested to participate in research projects [22, 27 - 28]. Readability tests using 
Flesh-Kincaid readability scales have also been suggested as a solution to dealing with 
consent forms that could not have been read and understood by prospective research 
participants with low literacy levels [40].  
2.2 Ethical challenges in obtaining informed consent in genetic and 
genomic research 
The above challenges in obtaining genuine informed consent in biomedical research also 
exist in genetic and genomic research. Specific ethical challenges in informed consent 
that have been identified in genetic and genomic research include the difficulty in 
explaining scientific methods and concepts such as “gene”, “genetics”, “genomics”, 
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“DNA”, “genetic database” and “data release” in local language during the consent 
process; the conduct of research in emergency situations which make standard consent 
processes impracticable especially where patients or their guardians are under stress; 
therapeutic misconception among research participants who are recruited in clinical 
settings and who have the widespread conception that research studies result in clinical 
benefit; and the trust that research participants have in medical doctors who are also 
researchers [1 - 2 40 - 44]. These ethical challenges are compounded by illiteracy, 
poverty, socio-cultural barriers and ineffective regulatory mechanisms in developing 
countries [45]. 
In addition, advances in genetic and genomic research have introduced new challenges 
in obtaining informed consent in research practice [46]. These include (1) granting broad 
or blanket consent for use of samples and data in future research the uses of which are 
not usually known at the time of giving consent [1,41 - 42]; (2) the difficulty in explaining 
data and sample sharing with researchers who were not part of the original study in which 
samples and data were collected; (3) the challenge of protecting the privacy and 
confidentiality of groups (i.e. families, communities or tribes); (4) the challenge of 
returning incidental or unrelated findings that were not part of the original research project 
to research participants [47 -49]; and (5) the difficulty in explaining risks not only to 
individual genomic research participants but also to their families, communities and even 
tribes in cases where members share the same genetic mutation associated with 
increased risk of stigmatization [1 – 2, 41 - 44]. In contrast to the above challenges, 
Marshall et al and Rotimi et al have found that patients with the genetic disease under 
study have a higher level of comprehension of the information disclosed during the 
consent process than healthy people in the control group due to their interaction with the 
health system because of their disease [43, 50]. 
Researchers and scientists have tried to suggest solutions to overcoming the above 
ethical challenges in obtaining informed consent in both genetic and genomic research. 
For instance, Aceme Nyika observes that prospective research participants do not 
necessarily have to understand the scientific jargon and concepts used in genetic and 
genomic research in order to comprehend the potential risks and benefits associated with 
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it [1]. He suggests that researchers have to be creative enough to explain the scientific 
jargon and concepts without necessarily explaining in detail the structures of genes and 
genomes and their processes. De Vries et al and Tekola et al acknowledge that these 
concepts can be linked to local knowledge of genetics, for example, that particular 
phenotypic traits are often inherited within families and communities [2, 44]. Other 
researchers have also suggested that communities involved in genetic and genomic 
research should be consulted and consented as part of community engagement before 
implementing any genetic and genomic research studies in their communities in order to 
address potential risks to such groups and protect their privacy and confidentiality [1, 41].  
In order to deal with the challenge of obtaining informed consent in emergency situations, 
Tindana et al suggest that researchers should observe conditions of prospective research 
participants and the emotional states of their guardians to ascertain an appropriate time 
to initiate the consent process [41]. In addressing the issue of sample sharing and data 
sharing among different researchers, it has been suggested that a governed approach to 
sample and data sharing should be developed prior to the implementation of genetic and 
genomic research [52] and the informed consent document should have options for 
withdrawal from research and data sharing plans [47]. There is also a suggestion that 
research staff who seek consent should be provided with additional specialized training 
so that they are able to explain in lay language the scientific concepts and methods used 
in such complex studies [1, 41 – 44, 50]. Some have suggested that the information 
sheets should contain a variety of different elements to ensure that research participants 
easily understand the disclosed information [47]. They say such elements should include 
a brief description of the research project, the goals of the research, the potential risks 
and benefits of participation, feedback of results and incidental findings and options for 
withdrawal from research as well as plans for data sharing. 
On the contrary, Chokshi et al have observed that it is difficult to create useful analogies 
in lay language for scientific methods and concepts to be used during the consent process 
in genetic research [42]. They argue that although several guidelines suggest that 
unfamiliar concepts should be explained using analogies during the consent process, 
there is no practical guidance for creating useful analogies for such unfamiliar concepts 
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as “gene”, “DNA”, or “genetic database”. Tindana et al have also observed similar 
challenges in explaining genomics in local language and in extrapolating knowledge of 
heredity to explain genomics where such research involves population level sampling that 
does not necessarily involve families affected by the genetic disease under study [41]. 
Community engagement activities have also shown little evidence of being successful in 
ensuring group confidentiality and in minimizing group risks in genetic and genomic 
research [43]. De Vries et al have also observed that ensuring that prospective research 
participants give informed consent for genomic studies still remains a significant 
challenge [2]. Although this work had started to highlight some of the complexities around 
seeking informed consent for genomics research, further empirical work was needed to 
understand a) how these challenges play out in different research contexts and 
populations and b) how they can be resolved. In fact, there are quite a few studies that 
have informed this discussion on ethical challenges in obtaining informed consent in 
genetic and genomic research and most of the studies reported in literature were 
theoretical [1 -3, 42 – 43, 46 – 49,53] while only four studies provide empirical data [41, 
44, 50 - 51]. Interestingly, there was virtually no empirical work that had been done in 
South Africa on local genomic research. 
2.3 Problem statement and justification 
Few studies have explored challenges in obtaining informed consent in genetic and 
genomic research in Africa, and the majority of these were theoretical not empirical. Such 
work cannot merely be extrapolated to the South African research context. Interestingly, 
there is virtually no work that has been done in South Africa on ethical challenges in 
obtaining informed consent for genomic research in particular. Therefore, to start filling 
this gap, we conducted an empirical study to investigate the efficacy of the informed 
consent procedures for a genomic study on Rheumatic Heart Disease that is currently 
being conducted in the Department of Medicine (FHS 466/2008) at the University of Cape 
Town. 
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2.4 AIM AND OBJECTIVES 
2.4.1 AIM 
The main aim of the study was to understand ethical challenges in obtaining informed 
consent in the RHDGen study. 
2.4.2 OBJECTIVES 
The specific objectives of the study were: 
1. To explore the ethical challenges in obtaining informed consent from prospective 
research participants in the RHDGen study. 
2. To explore what research participants understood during the consent process. 
3. To identify factors that could compromise voluntary decision-making for potential 
research participants in the RHDGen study.  
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3 METHODOLOGY 
3.1 INTRODUCTION 
In the previous chapter, I identified a number of important obstacles to obtaining genuine 
informed consent, and I observed that only a very limited number of studies on informed 
consent were conducted in the South African context, none of which examined participant 
comprehension in genomic research. In this project, I examined research participants’ 
understandings of the informed consent process for the RHDGen project. This chapter 
describes the research design, the location of research and the methods that were 
employed during data collection, data processing, data management and data analysis. 
It also explains the sampling strategies for the study participants, their demographic 
characteristics, methodological challenges, study limitations and ethical considerations 
that were encountered in this study. 
3.2 RESEARCH DESIGN 
The study used a cross-sectional study design to collect data from research participants. 
This design was appropriate for the study because data was collected from research 
participants at one point in time thereby allowing the acquisition of data in an open, flexible 
and inductive manner [54]. Since the main research question was to understand ethical 
challenges in obtaining informed consent in genomic research, the study was exploratory 
and descriptive in nature. 
3.3 LOCATION OF THE RHDGEN PROJECT 
The study participants were enrolled as cases and as controls in the RHDGen, a genomic 
research project on rheumatic heart disease. The RHDGen research project is recruiting 
both patients who have rheumatic heart disease and healthy people. Researchers in the 
RHDGen project are aiming to identify genetic factors of risk in patients who have 
rheumatic heart disease by comparing them with the genetic material and antibodies of 
people who do not have the disease. This will help them in designing an effective vaccine 
to prevent the development of rheumatic heart disease in people who are at risk of 
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developing the disease. As stated in section 1.1 above, the RHDGen research project is 
being conducted in 8 sub-Saharan African countries. The eight countries were chosen on 
the basis of having laboratory facilities for processing of DNA samples and throat swabs, 
and regulatory provision for export of biological materials for study in another country. 
These countries have already recruited 1087 unrelated probands with rheumatic heart 
disease as part of the REMEDY study. The recruitment of South African RHDGen cases 
and controls happened at four sites within the City of Cape Town in South Africa.  
3.3.1 RHDGen recruitment at Groote Schuur Hospital 
Groote Schuur Hospital is one of the largest tertiary hospitals of the Western Cape 
Province and it is a teaching hospital for the Faculty of Health Sciences of the University 
of Cape Town. The patient community served by this hospital comprises people from all 
racial backgrounds in South Africa, although the majority of patients are black and mixed 
ancestry South Africans from the Western Cape Province and largely from Cape Town. 
The RHDGen research project is recruiting both patients who were enrolled in a prior 
study, the Global Rheumatic Heart Disease Registry (REMEDY) study and new patients 
with rheumatic heart disease from the Cardiac Clinic at the Groote Schuur Hospital. 
Former REMEDY patients are identified through hospital records at the Cardiac Clinic by 
the research staff who are part of the RHDGen research project and work in the Cardiac 
Clinic as well. The new patients with rheumatic heart disease are identified by both the 
research nurse and study doctor who are part of the RHDGen research project and work 
in the Cardiac Clinic. Both the former REMEDY patients and new patients are approached 
to take part in the RHDGen research project as cases. The patients who are eligible and 
show interest to participate in the RHDGen research project are either recruited into the 
RHDGen research project on the same day they are approached or are booked for 
recruitment on specific dates at the Clinical Research Centre (J52) of the Old Main 
Building of the Groote Schuur Hospital. This study on ethical challenges in obtaining 
informed consent in the RHDGen research project targeted both former REMEDY 
patients and new patients that were recruited into the RHDGen research project. 
Participant observations (POs) were conducted during the consenting of the patients for 
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participation into the RHDGen research project and in-depth interviews (IDIs) were done 
with some of the patients. 
Some controls for the RHDGen research project were recruited at the Clinical Research 
Centre located in the Old Main Building of the Groote Schuur Hospital. All study 
procedures for controls such as the consent process, recruitment and study specific 
procedures at the Groote Schuur Hospital were done in the Clinical Research Centre. 
The controls for the RHDGen research project came to the Clinical Research Centre in 
response to advertisements about the study which were posted around the Groote Schuur 
Hospital. The adverts contained introductory information about the study, the purpose of 
the study and the eligibility criteria for the study. Potential controls who read the adverts 
and were interested to participate in the study were invited to come to the Clinical 
Research Centre (J52) of the Old Main Building of the Groote Schuur Hospital for 
recruitment. When the potential controls arrived at the Clinical Research Centre, they 
were taken through the consenting process after their obtaining their consent, the 
research nurse collected their blood samples in one room.  
Demographic information such as age, ethnicity, mother tongue, area of origin, height, 
weight and blood pressure as well as completion of the case report forms (CRFs) were 
done by the field officer in the second room. After that, study participants went to the third 
room where the echo-cardiologist or study doctor performed echocardiograms (ECHOs). 
When they were done with study related procedures, study participants left the Clinical 
Research Centre. Some controls recruited at the Clinical Research Centre who were not 
based at the Groote Schuur Hospital or the Faculty of Health Sciences were given 
transport refunds to their homes. 
3.3.2 RHDGen recruitment at Vanguard Community Health Centre 
The Vanguard Community Health Centre is a primary healthcare facility located in 
Bonteheuwel and serves mostly Xhosa speaking South Africans from the Langa area in 
Cape Town. Some controls for the RHDGen research project were recruited at the 
Vanguard Community Health Centre. The consent process, recruitment and study 
procedures for controls at the Vanguard Community Health Centre were done in a bus 
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which was previously being used as a mobile van for the Awareness, Surveillance, 
Advocacy and Prevention (ASAP) program for kids’ heart health by the Department of 
Medicine at the University of Cape Town. The bus/van is divided into three compartments. 
For the RHDGen research project, the first compartment was used for consenting 
potential study participants, taking blood samples, weight, height, age, ethnicity, area of 
origin and mother tongue. The first compartment was also used as a waiting area for 
study participants before they went to the second compartment. In some cases, it was 
also used as a waiting area for potential study participants who were yet to be consented 
and recruited into the RHDGen research project. The second and third compartments 
were used for performing echocardiograms and electrocardiograms respectively. 
Recruitment at the Vanguard Community Health Centre started with a talk which was 
given by the field officer for the RHDGen research project to patients who were waiting to 
consult clinicians at the Out Patient Department (OPD) waiting area of the Health Centre. 
The talk centred on the introduction, purpose, study procedures and the eligibility criteria 
for controls of the RHDGen research project. At the end of the talk, patients were given a 
chance to ask questions about the study. Patients were also asked to read an information 
leaflet about the study which was posted on the notice board of the Health Centre for 
detailed information. Finally, potential study participants who met the eligibility criteria and 
were interested to participate in the study were invited to come to the bus for consenting 
and study related procedures. 
3.3.3 RHDGEN recruitment at Heideveld Community 
The Heideveld Community is a community of coloured (mixed ancestry) South Africans 
in Cape Town. Potential study participants for the RHDGen research project at the 
Heideveld community were identified by a community leader. The community leader 
together with his assistants wrote down names of potential study participants they 
identified. The potential study participants were asked to come to the bus, which was 
normally parked at one of the flats of the community, at a time convenient to them. When 
the potential study participants arrived, they were given information about the RHDGen 
research project by either a nurse or the field officer. The nurse or field officer introduced 
the RHDGen research project to them, explained the study related procedures and 
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eligibility criteria. The potential study participants were also handed the information 
leaflets for the study to read and they were asked to consult any of the study staff if they 
had any questions about the study. Those who expressed willingness to participate in the 
study entered the first compartment for consenting and other study related activities. They 
continued with the study related procedures in the second and third compartments in the 
same way as described earlier. When they were done with the RHDGen study-related 
procedures, the study participants were given refreshments such snacks and juices. 
3.4 RESEARCH PARTICIPANTS 
Many genetic and genomic research projects recruit both cases and controls. The 
rationale for recruiting both cases and healthy controls is to compare samples from 
patients who have the disease under study with samples from people who do not have 
the disease. Researchers study the genetic material (DNA and RNA) and antibodies of 
both groups in order to establish the genetic difference or mutations between the two 
groups that make some people develop the disease and the other people healthy. This 
difference in genetic make-up enables researchers or scientists to come up with 
interventions to mitigate the development of the disease in people who have the genetic 
mutations and might develop the disease. This is why the RHDGen research project 
recruits both cases and controls. The current study targeted both RHDGen cases and 
controls. 
3.4.1 RHDGen cases 
The RHDGen cases are both REMEDY patients and new patients with rheumatic heart 
disease recruited from the Cardiac Clinic at the Groote Schuur Hospital. This study has 
conducted observations of the consent process of the RHDGen cases and in-depth 
interviews with some of the study participants. 
3.4.2 RHDGen controls 
As described in section 3.3, controls for the RHDGen research project were recruited at 
the Vanguard Community Health Centre in Bonteheuwel, the Heideveld Community in 
the Cape Flats and the Clinical Research Centre of the Groote Schuur Hospital. All the 
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controls for the RHDGen research project were people who did not suffer from any chronic 
diseases and did not have any heart problem during the time of recruitment. In this study 
on informed consent, we conducted observations of the consent process and in-depth 
interviews with RHDGen study participants across all these RHDGen recruitment sites. 
3.4.3 RHDGen staff as key informants 
This study also recruited RHDGen staff who were involved in obtaining consent and 
recruiting both RHDGen cases and controls. The RHDGen staff were recruited and 
interviewed at the Clinical Research Centre. 
3.5 DATA COLLECTION METHODS 
A combination of two qualitative research methods – in-depth interviews (IDIs) and 
participant observations (POs) were employed in the study. An in-depth interview is a 
dialogue or a conversation between an interviewee and an interviewer in which there are 
several selected themes of interest based on a pre-determined question guide [55]. 
During the interview, the interviewer does not need to ask questions in a particular way 
and the interviewee (respondent) can answer in any way she/he likes and he/she can be 
probed when it is needed. In a participant observation, the observed are less involved 
and the observer has the freedom to direct his or her attention in the direction which 
seems most appropriate [55]. In qualitative studies, observational data is as important as 
interview data; in fact, the two types of data are closely linked, as qualitative researchers 
might use interviews to make sense of what they observe, and observation to interpret 
their interview data [56]. Qualitative researchers also use participant observation as a 
data collection method when it complements other forms of data collection methods [56]. 
The qualitative study approach employed in this study allowed the student to derive in-
depth information from study participants [57]. 
3.5.1 IN-DEPTH INTERVIEWS (IDIs) 
As described earlier, this study recruited RHDGen cases and controls as well as RHDGen 
staff involved in the consent process and recruitment of RHDGen cases and controls. 
Before conducting each IDI, individual written informed consent was obtained from each 
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of the respondents and a demographic data form was administered to document 
respondents’ age, sex, highest education achieved, occupation, religion, first language, 
the location where the respondent was living, the type of respondent and the time since 
the study participant was recruited into the RHDGen research project. These 
demographic data were important for the student during the analysis process of the 
interviews because they allowed the student to compare the responses from the different 
study participants based on their demographic information. The student and a Research 
Assistant conducted the IDIs with RHDGen controls that were enrolled at the Clinical 
Research Centre in the Old Main Building of the Groote Schuur Hospital. One of them 
moderated the interviews while the other took notes, recorded observations and assisted 
in probing the respondents. Semi-structured interview guides were used in a flexible way 
to guide the interviews with cases and controls recruited into the RHDGen research 
project and research staff in order to get in-depth knowledge and experience on the 
consent process. The interview guides had sets of pre-determined and open-ended 
questions and the questions were formulated using the study objectives and they were 
being revised as the data collection progressed. The semi-structured interview guides 
allowed the student to control the line of questioning, which was especially useful for a 
qualitative study, and to follow-up on aspects that emerged during the course of the 
interviews [58]. 
The IDIs with cases in the Cardiac Clinic of the Groote Schuur Hospital and with controls 
at the Vanguard Community Health Centre and the Heideveld Community as well as with 
research staff were conducted by the student. The IDIs were conducted in English and 
consent was obtained for recordings. The audio-recordings were later transcribed 
verbatim by the student. Notes were taken and observations were recorded at each 
interview. All interviews were conducted on the day of enrolment in the RHDGen study. 
IN-DEPTH INTERVIEWS WITH RHDGEN CASES AND CONTROLS 
Both male and female cases and controls recruited into the RHDGen research project 
were included in this study. For the RHDGen cases, the IDIs were conducted in the 
recruitment room located in the Cardiac Clinic of the Groote Schuur Hospital. Twelve (12) 
IDIs were conducted there with RHDGen cases. For RHDGen controls, IDIs were 
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conducted either in the front seat of the van which was used for recruitment at the 
Vanguard Community Health Centre and the Heideveld Community or in the meeting 
room of the Clinical Research Centre in the Old Main Building of the Groote Schuur 
Hospital. Twenty (20) IDIs were conducted with RHDGen controls at the Vanguard 
Community Health Centre (9), Heideveld Community (5) and the Clinical Research 
Centre in the Old Main Building of the Groote Schuur Hospital (6). In total, 34 IDIs were 
conducted with RHDGen cases and controls. 
IN-DEPTH INTERVIEWS WITH RESEARCH STAFF 
The study also targeted research nurses who were responsible for consenting potential 
RHDGen cases and controls. The research nurses were scheduled for IDIs at the time of 
their convenience. Two (2) IDIs were conducted with research nurses involved in the 
consenting and recruitment of RHDGen cases and controls. Both IDIs with research 
nurses were conducted by the student. 
In total, 91 study participants were recruited into the study. Thirty-four (34) respondents 
took part in the in-depth interviews while 57 participants took part in the observations. 
Most of the IDI respondents were female (see table 2 below). This could be attributed to 
the fact that more women attended the health care facilities than men during the period 
of data collection. Most of the respondents were within the age range of 18 to 40 and had 
completed secondary school education. Two-thirds of the respondents were employed 
and the majority was of the Christian faith. There was an almost equal division between 
Xhosa and Afrikaans as first language. Those that indicated Afrikaans as first language 
generally also spoke good English. The study targeted both Xhosa and Afrikaans 
speakers who could also speak English. Non-English speakers were not included in the 
study. 
Below is a table showing the in-depth interviews conducted with the RHDGen research 
participants in each site. 
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Table 1: LIST OF ALL IN-DEPTH INTERVIEWS BY SITE 
CASES – GSH 
(N=12) 
CONTROLS – 
GSH/CRC 
(N=6) 
RESEARCH 
STAFF 
GSH/CRC 
(N=2) 
CONTROLS 
VANGUARD HC 
(N=9) 
CONTROLS 
HEIDEVELD 
(5) 
CWR 14 COC 05 RS_1 COV 01 COH 26 
CWR 15 COC 06 RS_2 COV 02 COH 27 
CWR 16 COC 07  COV 03 COH 30 
CWR 17 COC 08  COV 04 COH 31 
CWNR 18 COC 20  COV 09 COH 32 
CWR 19 COC 21  COV 10  
CWR 22   COV 11  
CWNR 23   COV 12  
CWR 24   COV 13  
CWR 25     
CWR 28     
CWR 29     
 
KEY 
COC = Control recruited at the Clinical Research Centre 
COH = Control recruited at the Heideveld Community 
COV = Control recruited at the Vanguard Community Health Centre (Bonteheuwel) 
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CWR = Remedy patient (Case) recruited in the Ward at the Groote Schuur Hospital (E17) 
or at the Clinical Research Centre 
CWNR = Non-Remedy patient (Case) recruited in the Ward at the Groote Schuur Hospital 
(E17) or at the Clinical Research Centre 
 
3.5.2 PARTICIPANT OBSERVATIONS (POs) 
In addition to in-depth interviews, we also conducted a large number of participant 
observations for this project. All POs were conducted by the student. For the POs, the 
research nurse administering the consent process introduced the student orally before 
commencing the RHDGen consent process. The student then sought verbal consent from 
each potential research participant for his presence during the consenting process. All 
participants in the POs were given an information leaflet to inform them about the study. 
During the observations, the student took notes which were typed up immediately after 
the observations. The information obtained in the POs informed the topic guides for IDIs 
with both RHDGen research participants and research staff. Some of the POs were 
succeeded by IDIs with both RHDGen cases and controls. 
The POs with RHDGen research participants were conducted at the same venues where 
they were recruited into the RHDGen research project while the IDIs with research staff 
were conducted at the Clinical Research Centre in the Old Main Building of the Groote 
Schuur Hospital. 
Data were collected from RHDGen research participants and research staff for a period 
of 5 months from July to November 2014. 
PARTICIPANT OBSERVATIONS WITH RHDGEN CASES AND CONTROLS 
The student observed 14 consent procedures of RHDGen cases in the Cardiac Clinic at 
the Groote Schuur Hospital and 43 consent procedures of RHDGen controls at the 
Vanguard Community Health Centre (21), Heideveld Community (18) and the Clinical 
Research Centre in the Old Main Building of the Groote Schuur Hospital (4) (see Table 2 
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below). In total, 57 POs were conducted during the consent procedures and recruitment 
of both RHDGen cases and controls by the student. The POs were conducted at the 
venues where informed consent from the RHDGen cases and controls was obtained. The 
results of this part of the study are reported in the subsequent Chapters of the thesis. 
 
Table 2: OVERVIEW OF RESEARCH PARTICIPANTS RECRUITED 
 
 
Table 3: DEMOGRAPHIC CHARACTERISTICS OF STUDY PARTICIPANTS 
DEMOGRAPHIC CHARACTERISTICS IDI RESPONDENTS 
(N= 34) 
Sex 
Male 
Female 
 
10 
24 
Age 
18 – 40 
 
21 
DATA 
COLLECTION 
METHODS 
GROOTE SCHUUR HOSPITAL VANGUARD HC 
(CONTROLS) 
HEIDEVELD 
COMMUNITY 
(CONTROLS) 
TOTAL 
CASES CONTROLS STAFF 
Observations 14 4 NA 21 18 57 
In-Depth 
Interviews 
12 6 2 9 5 34 
TOTAL 91 
34 
 
41 - 60 13 
 First Language 
Xhosa 
Afrikaans 
English 
 
17 
14 
3 
Occupation 
Employed 
Not employed 
 
23 
11 
Religion 
Christian 
Moslem 
Non-religious 
 
26 
6 
2 
Highest Education Achieved 
Primary 
Secondary 
Tertiary 
 
2 
24 
8 
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3.6 DATA PROCESSING AND MANAGEMENT 
All interviews were conducted in English. The duration of the shortest in-depth interview 
was 25 minutes while the longest interview lasted 45 minutes. The shortest participant 
observation took 15 minutes while the longest lasted 30 minutes. The majority of 
interviews (n=28) were transcribed verbatim by the student. A small number of interviews 
(n= 6) were not transcribed. These interviews were either very short or did not add insight 
into the topic of study – for instance, because the respondent only answered ‘yes’, ‘no’ or 
‘I don’t know’ and some of the respondents seemed not to be interested in answering the 
questions that were being asked. To ensure that no valuable information was lost, the 
student listened to all the audio-recordings that were not transcribed when all other 
interviews were coded hierarchically and took note of any additional important content. 
Each transcript had a preamble or summary of the interview followed by a verbatim 
transcription of the audio-recording with two key letters, I and R to stand for interviewer 
and respondent respectively. The summary of each interview was informed by the notes 
that were taken during the interviews. All transcripts were imported into NVivo 10 for 
analysis. 
The student took notes during the POs and typed up the notes immediately after each 
PO. The written notes from the POs were read thoroughly by the student in order to 
understand the dynamics in the recruitment and consenting process of the RHDGen 
participants. 
3.7 ANALYSIS OF INTERVIEW DATA 
Thematic content analysis was used to analyse interview data. The analysis was iterative 
and preliminary analysis started when the initial interviews were transcribed. The analysis 
was inductive. The inductive process involved the following steps: 
●Thorough reading of transcripts for familiarization with the data: the student read 10 
transcripts from the IDIs as well as field-notes in order to understand what was coming 
out of the interviews. Issues that emerged and needed elucidation were probed in 
subsequent interviews. 
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●Transcripts were imported into NVIVO software and free-coded. The free codes were 
recorded in the student’s codebook. Free codes were discussed with the supervisor, who 
also read a number of interviews together with the free codes. Based on these 
discussions and insights from the first round of coding, a coding framework was 
developed. The coding framework was applied to the transcripts by grouping together 
similar responses, a process described by Creswell as taking apart texts or qualitative 
information and looking for categories, themes or dimensions of information [59]. The 
quotes for each code were reviewed and any excerpts that were not categorized with the 
coding framework were given a new code. In case of doubt or un-clarity, the codes and 
their quotes were discussed with the supervisor. 
●Searching themes from the initial codes: the free (initial) codes were read again and 
grouped into hierarchical coding scheme. The higher codes were grouped into main 
themes with the lower nodes as their sub-themes. The transcripts were re-coded using 
this new hierarchical coding scheme. Memos were written for each hierarchical code. The 
quotes for each theme were reviewed and discussed with supervisor. 
●Production of data summaries and charting: data summaries were produced from the 
texts. The data summaries comprised main themes and their sub-themes as well as their 
quotes as examples from the texts. The data summaries were discussed with the 
supervisor and from the discussions, a charting framework was developed with linkages 
to the data. The charts were produced for each main theme and sub-theme. The charts 
were also compared across all themes. Each chart was given a descriptive account of 
each theme and had relevant quotes from the study participants. 
●Writing of empirical chapters: the charts were used to develop a first account of the 
empirical data, which was discussed with the supervisor. Subsequent drafts re-examined 
the data and the charts, and integrated emerging insights into the analysis. 
3.8 METHODOLOGICAL CHALLENGES AND STUDY LIMITATIONS 
One limitation of the study was the dual role played by the research student. The student 
was both a member of the RHDGen project team and an ethics researcher on the project. 
As a team member, he was sometimes asked to assist the research staff in completing 
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some of the study related procedures for potential research participants such as recording 
weight and height, explaining the study to potential study participants and completing the 
enrolment logs for controls. As such, study participants thought that the IDIs and POs 
were part of the RHDGen research project procedures and this might have affected the 
way they responded to the questions in the IDIs. They might have also felt obliged to 
respond to the questions in the interviews although they had to give a separate consent 
for participating in the interviews. Related to this limitation is the challenge of the research 
student as an embedded ethicist. The research student assisted the field officer and 
research nurses in completing some study related procedures for research participants 
whilst at the same time he was also actively observing how the consent process was 
being conducted by the other research staff in order to take note of ethical challenges in 
obtaining consent from the potential research participants. In cases where the research 
student observed that the consenting process was not properly done or that they were 
some challenges in obtaining informed consent, he initially sought to discuss these with 
the research staff to improve practice. However, it became clear that the research 
student’s intervention caused some resentment among some research staff and there 
was a risk that they would henceforth resist having the research student present during 
the recruitment process. This was partly resolved by an intervention by one of the project 
supervisors who intervened by talking to the research staff to explain the purpose of the 
study and to assure them that the research student was not there to spy on them. From 
that moment on, the student recorded challenges or shortfalls in the consent process, but 
did not intervene or comment on the quality of the consent process to the study staff. 
However, balancing this tension between on the one hand knowing, from literature and 
experience, how the consent process ought to be conducted, and on the other hand 
observing imperfect processes remained a challenge throughout this project. In the 
results section of the thesis, I will give an account of the challenges encountered by 
research staff in patient recruitment.  
A second limitation was that we did not recruit people who refused to participate in the 
RHDGen research project to understand why they refused to participate. This was outside 
of the scope of this study since our aim was not to understand why some people refused 
to participate in the RHDGen research project.  
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A third important limitation is that interviews were conducted in English. Some of the study 
participants who had said that they could speak English were in fact not very fluent in 
English, and for others speaking in a second language may have complicated explaining 
issues relating to genomics. This was mostly a problem among Xhosa speakers that were 
recruited at the Vanguard Community Health Centre. 
3.9 ETHICAL CONSIDERATIONS 
Ethics approval was obtained from the Human Subjects Research Review Committee in 
the Faculty of Health Sciences at the University of Cape Town. Written individual consent 
was obtained from each of the study participants prior to their participation in the IDIs 
while verbal consent was obtained from all the participants who participated in the 
participant observations. Verbal consent was obtained from the potential research 
participants to have the consent process observed because the student did not interact 
with the study participants during the consent process other than observing the consent 
process. However, individual written informed consent was sought from each of the 
research nurses administering the consent procedures once before the first participant 
observation was conducted. All the participants in the study were given codes to ensure 
privacy and confidentiality and the data collected were kept in the student’s office and 
computer located at the Clinical Research Centre in the Old Main Building of the Groote 
Schuur Hospital. 
One of the ethical concerns in this study was that two RHDGen controls recruited from 
the Heideveld Community refused to put their signatures on the consent documents 
despite the fact that they were literate and they had given their consent to participate in 
the study. Instead the student urged the study participants to thumb-print the consent 
document but they also refused. When the student asked the study participants why they 
did not want to put their signatures on the consent documents, they explained that they 
wanted to stick to what the student had told them about confidentiality and the fact that 
they did not want to have their names written on the consent documents. As such, the 
student documented in the consent form that the participants had consented to taking 
part in the study but that they refused to sign the consent form. 
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Another challenge was that some RHDGen cases in the Cardiac Clinic at the Groote 
Schuur Hospital and controls at the Vanguard Community Health Centre were in a hurry 
and they did not want to spend much time during the consent process and the IDIs. Such 
study participants wanted to sign the consent document immediately after being 
introduced into the study since they felt that they had already heard about the study and 
that the consent process and interview might take much of their time as they were on 
queues waiting to see doctors. In order to address this issue, the student asked such 
potential study participants to suggest the time they would be free to go through the 
consent process and to have the interviews. In most cases, such potential study 
participants agreed to go through the consent process and granted the interviews though 
they did not participate fully in the interviews. 
3.10 SUMMARY 
In this study exploring perspectives on and comprehension of the RHDGen consent 
process, the research student conducted in-depth interviews and participant observations 
with research participants in the RHDGen project. A total of 34 IDIs and 57 POs were 
conducted with RHD patients and healthy population controls. Data from these two 
methods were analysed inductively using computer-assisted thematic analysis. In the 
next chapter, I will describe my analysis from the participant observations before moving 
on, in Chapter 5, to a description of the interview data. 
4 OUTCOMES OF PARTICIPANT OBSERVATIONS OF THE 
CONSENT PROCESS OF RHDGEN CASES AND 
CONTROLS 
4.1 Introduction 
As described in the methods chapter, observations of the consent process of both 
RHDGen cases and controls were conducted in the Cardiac Clinic and Clinical Research 
Centre at the Groote Schuur Hospital, the Vanguard Community Health Centre and the 
Heideveld Community. This chapter discusses the different contexts where recruitment 
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and consent of RHDGen research participants took place and the ethical challenges that 
arose in these different recruitment contexts. It also describes how the different 
recruitment contexts impacted on the RHDGen research staff’s ability to seek proper 
informed consent and the research staff’s attitudes to both RHDGen cases and controls. 
4.2 Different recruitment contexts of RHDGen cases and controls 
The recruitment of RHDGen participants was conducted in both health facility and 
community settings. As described in section 3.3 of the methods chapter, the recruitment 
happened across all the four sites within the City of Cape Town in the Western Province 
of South Africa, all of which had very different features. 
4.2.1 Recruitment and consent process of RHDGEN cases in the Cardiac Clinic and 
the Clinical Research Centre at the Groote Schuur Hospital 
Recruitment of RHDGen cases in the Cardiac Clinic and the Clinical Research Centre 
was done by the RHDGen research nurse and study doctor. At the beginning of each 
consent procedure, the research nurse or study doctor provided information about the 
RHDGen research project to prospective research participants. She/he explained the 
purpose of the RHDGen research project, the potential benefits, foreseeable risks and 
study-related procedures such as collection of blood samples, blood pressure, height and 
weight as well as performance of ECHOs and electrocardiograms (ECGs) to scan the 
heart. Most research participants appeared to have understood the information which was 
provided. She/he also gave an opportunity to the research participants to ask questions 
or seek any clarifications about the study. The information provided to the prospective 
research participants by the research nurse or study doctor in the Clinical Research 
Centre was similar to the information which was provided to prospective research 
participants in the Cardiac Clinic. However, the research nurse or study doctor took much 
more time to discuss the RHDGen research project with prospective research participants 
in the Clinical Research Centre than in the Cardiac Clinic. In the Clinical Research Centre, 
she was able to articulate the study-related procedures and the rationale for the different 
procedures. In the Cardiac Clinic prospective research participants were to consult their 
doctors whom they had come to see on appointment and they were sitting in a queue 
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when the research nurse or study doctor approached them to take part in the RHDGen 
research project. Some had already been informed of the study telephonically. Unlike in 
the Cardiac Clinic, prospective research participants in the Clinical Research Centre were 
at ease and patient to go through the consent and recruitment process because they had 
come solely for the consent and recruitment process into the RHDGen research project. 
These facts impacted on how the research nurse and study doctor conducted the consent 
and recruitment process. In the Cardiac Clinic, they had to conduct the consent and 
recruitment process quickly so that the prospective research participants could go back 
to their queue while in the Clinical Research Centre, they took their time to take the 
prospective research participants through the consent and recruitment process. 
4.2.2 Recruitment and consent process of RHDGen controls at the Clinical 
Research Centre of the Groote Schuur Hospital 
Study procedures for RHDGen controls at the Clinical Research Centre were the same 
as those for RHD patients recruited in the Clinical Research Centre. The controls came 
to the Clinical Research Centre in response to adverts about the study which were posted 
around the Groote Schuur Hospital (refer to figure 1 below) and after being informed by 
their friends or colleagues about the study. The posters had introductory information 
about the RHDGen research project including the purpose of the study, eligibility criteria 
and study-related procedures. Prospective research participants, who read the posters or 
were informed by friends and colleagues about the study and got interested to join the 
study, came to the Clinical Research Centre (J52) of the Old Main Building of the Groote 
Schuur Hospital for recruitment. 
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Figure 1: Advert about the RHDGen study on the notice board of the Groote Schuur 
Hospital 
 
In contrast to the recruitment of patients (cases) in the Cardiac Clinic at the Groote Schuur 
Hospital, there was no oral information provided to prospective research participants 
(controls) enrolled at the Clinical Research Centre because the prospective research 
participants had already heard about the study from either their friends/colleagues or the 
adverts that were posted on the notice boards at the Groote Schuur Hospital. Instead 
when the prospective research participants arrived at the Clinical Research Centre, they 
were taken through the consenting process by the research nurse who also collected 
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blood samples for genetic tests in one room. After that, the recruited research participants 
went to the second room where the field officer obtained demographic information such 
as age, ethnicity, and mother-tongue, area of origin, height, weight and blood pressure. 
From the second room, the research participants went to the third room where the echo-
cardiologist or study doctor performed ECHOs and ECGs. When they were done with all 
study related procedures, the research participants left the Clinical Research Centre. The 
research nurse had enough time to explain the RHDGen study to prospective research 
participants and most research participants seemed to be educated and understood what 
a genetic study meant. Most prospective research participants were also inquisitive to 
learn what the RHDGen research project was all about. Unlike controls that were recruited 
at the Vanguard Community Health Centre and the Heideveld Community, controls that 
were recruited at the Clinical Research Centre and were not based at the Groote Schuur 
Hospital or the Faculty of Health Sciences were given transport refunds. 
4.2.3 Recruitment and consent process of RHDGen controls at the Vanguard 
Community Health 
A third location of participant recruitment was at the Vanguard Community Health Centre. 
Before recruitment and consent process of controls at the Vanguard Community Health 
Centre, the RHDGen field officer introduced the RHDGen research project to prospective 
research participants who came as patients to access services at the Vanguard 
Community Health Centre. The talks were given at the waiting area in the Out Patient 
Department where patients waited to see clinicians at the Health Centre and they were 
done in both Xhosa and English. During the talks, the field officer introduced himself and 
explained that a study was being conducted that targeted healthy adult people to find out 
if they had rheumatic heart disease (RHD). He referred them to the posters on the walls 
of the Health Centre which had information about the RHDGen research project. He went 
on to explain the benefit of participating in the study as being that study participants would 
know whether they had a rheumatic heart disease or not. He also highlighted that ECHOs 
and ECGs were being performed as part of the study to confirm rheumatic heart disease. 
He articulated that the ECHOs and ECGs were expensive at private hospitals or clinics 
and that the study was providing such services free of charge. He also alluded to the fact 
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that community members always complained about health services not being made 
available to them and that the UCT Groote Schuur Hospital was bringing such services 
to their doorsteps at the Vanguard Health Centre. He also explained that patients who 
would be confirmed to have RHD during the ECHOs and ECGs would be referred to the 
Groote Schuur Hospital for further treatment. Finally, he invited prospective research 
participants who were interested to participate in the study to go to the van which was 
parked outside the Health Centre close to the main entrance of the Hospital for 
recruitment. 
After going through all the study-related procedures, each recruited research participant 
left the study site (van) and the research nurse or field officer proceeded with 
consent/recruitment of other prospective research participants. 
Figure 2: Picture of the bus at the Vanguard Community Health Centre 
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4.2.4 Recruitment and consent process of RHDGen controls at the Heideveld 
Community 
Prospective research participants for the RHDGen study at the Heideveld Community 
were identified by a community leader. The community leader together with his assistants 
wrote down names of prospective research participants they identified. The potential 
research participants were asked to come to the bus/van, which was normally parked at 
one of the Flats of the community, at their convenient time. When the prospective 
research participants arrived at the van, they were given information about the RHDGen 
study by either the research nurse or the field officer. The research nurse or field officer 
introduced the RHDGen study to them, explained the study related procedures and the 
eligibility criteria. The potential research participants were also handed the information 
leaflets for the study to read and they were asked to consult any of the research staff if 
they had any questions about the study. There was no detailed information provided to 
the prospective research participants at this stage because most of them had already 
heard about the RHDGen study from their community leader and the adverts that were 
distributed in their community prior to recruitment. Those who expressed willingness to 
participate in the study entered the first room for consenting and other study related 
activities in the same way as they did at the Vanguard Community Health Centre. They 
continued with the study related procedures in rooms B and C. When they were done with 
the study procedures, the research participants were given refreshments such as snacks 
and juices. Almost all the recruited research participants at the Heideveld Community 
were coloured or of mixed ancestry. 
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Figure 3: Picture of the bus at the Heideveld Community 
 
4.3 Specific ethical challenges with the informed consent process of 
RHDGen cases and controls in the different recruitment sites 
4.3.1 Fear of giving blood 
Research participants recruited in the Cardiac Clinic felt that the volume of blood which 
was being collected by the research nurse and study doctor for the RHDGen study was 
too much. The research nurse and study doctor collected 9 mls of blood from each 
research participant in three EDTA tubes of 3 mls each. Some research participants felt 
this amount of blood was a lot. This was because during their appointments with doctors 
in the Clinic, doctors also took 5 mls of blood for clinical purposes. As such, some 
research participants were afraid to give their blood for the RHDGen study. In some 
cases, these concerns led to some potential participants not being enrolled into the 
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RHDGen study although they had already given their consent to join the study and had 
gone through the other study-related procedures. 
4.3.2 Trust and familiarity with research staff 
Most patients recruited in the Cardiac Clinic seemed to trust clinicians (doctor and nurse) 
who were part of the RHDGen research team because of their familiarity with them in the 
clinic. It was evident during the consent process that the prospective research participants 
had trust in the study doctor and study nurse and did not pay attention to the disclosure 
of information about the study. Some prospective research participants even told the 
study nurse and study doctor to proceed with the study related procedures before she/he 
finished providing information about the study. Familiarity with the field officer who was 
part of the RHDGen research staff also played a role in the recruitment of controls at the 
Vanguard Community Health Centre. Some controls knew the field officer personally 
while others used to see the field officer in their community. Because of their familiarity 
with the field officer, most prospective research participants willingly presented 
themselves to the van for recruitment after he had provided them with information about 
the study. 
4.3.3 Diagnostic misconception among prospective research participants 
According to the observations, most prospective research participants came to the van 
and the Clinical Research Centre for recruitment because they wanted to be screened for 
rheumatic heart disease and other heart conditions. They wanted to access the free 
ECHO and ECG services that were available to prospective research participants since 
they were informed that such services were quite expensive in private hospitals. It was 
clear from the observations that most prospective research participants did not pay 
attention to the information which was being disclosed to them during the consent process 
and they were very eager to go through the ECHOs and ECGs. After the heart scans, 
most research participants were very happy that they did not have any heart problems. 
They were so happy that one could think they had passed an examination. It was also 
observed that some prospective research participants were motivated by the information 
that they would be referred to the Groote Schuur Hospital if they were found to have 
48 
 
rheumatic heart disease or any heart conditions during the ECHO and ECG services. 
From the information provided by the field officer, some prospective research participants 
might have also thought the study was a health service brought to their communities to 
know whether they had a RHD or not. This observation was common among research 
participants recruited at the Heideveld Community. From the information provided by the 
community leader to the prospective research participants in Heideveld Community, it 
was clear that prospective research participants thought the study was a health service 
brought to their community in order to screen them for RHD. It was evident from the 
prospective research participants that the members of the research team had gone to 
their community to screen them for rheumatic heart disease. However, the community 
leader’s role was to mobilize prospective research participants to come to the recruitment 
site where they would be provided with detailed information about the study before being 
recruited into the RHDGen study. 
4.3.4 Privacy and confidentiality 
As explained above, consent and collection of personal information from prospective 
research participants at the Vanguard Community Health Centre and the Heideveld 
Community were done in the presence of other prospective research participants and 
recruited research participants in the van. This might have compromised privacy and 
confidentiality of research participants. In fact, the van did not provide physical space that 
would respect privacy and confidentiality of prospective research participants. This was 
due to the limited space which was available for conducting study related activities in the 
two sites. 
4.3.5 Pressure during the recruitment process 
In most cases, the research staff were under pressure to recruit the potential research 
participants because they would normally come in their large numbers and queue for 
recruitment. There was pressure on the research nurses obtaining consent to do the 
process as quickly as possible because the prospective research participants were 
always eager to go back to the clinic to see their clinicians in the case of Vanguard 
Community Health Centre and they did not want to be delayed further with the recruitment 
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process. As such, in some cases, the consent process was done hurriedly and the 
prospective research participants were not provided with sufficient/adequate information 
about the study in order for them to make an informed decision. This might have affected 
prospective research participants’ comprehension of the information about the study and 
could have compromised their voluntary decision-making process. Of course, research 
participants’ understanding of the study and their voluntary decision-making were 
explored further in the in-depth interviews that were conducted with the research 
participants as part of this study on informed consent. 
Due to the queues, research participants waited for long to go through the study related 
procedures i.e. blood draws, BP measurement and record of their height and weight. Due 
to the long waiting times, some recruited research participants decided to leave before 
completing the study procedures because they became impatient and tired of waiting 
since they had gone to the van before they had consulted the clinicians at the Health 
Centre and felt they were being delayed further or would miss being seen by the clinicians 
at the Health Centre. Some research participants I talked to expressed this dissatisfaction 
with the long waiting times. However, there was no way the research staff could have 
hurried the study related procedures for the research participants. 
4.3.6 Undue inducement to participate in the RHDGen research project 
As stated above, prospective research participants in the Heideveld Community were 
identified by the community leader or his assistants. The community leader was asked to 
identify a specific number of prospective research participants to be recruited in the 
community on each day of recruitment. Having talked to some of the prospective research 
participants and from the information provided by the field officer, it was apparent that 
prospective research participants thought that the study was a health service being 
provided to them to know whether they had RHD or not. The prospective research 
participants confirmed that the community leader informed them that doctors from the 
Groote Schuur Hospital were coming to screen people in the community for rheumatic 
heart disease and most prospective research participants who came to the site wanted 
to know whether they had RHD or not and they were motivated by the fact that the ECHOs 
and ECGs were free and that these services had been brought to their community. 
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Information and emphasis on free health service and referral to the GSH for further 
treatment for prospective research participants with confirmed RHD could have also 
unduly induced prospective research participants to join the study. Some of the features 
that were observed in this community that might have contributed to this ethical challenge 
were the high levels of unemployment and crime among the residents as well as poverty 
and limited access to health care. 
4.3.7 Refusal to disclose names and sign consent documents 
Some of the research participants in the Heideveld Community refused to provide their 
names and sign the consent documents during the consenting process although they had 
given their verbal consent to participate in the study. This was common among young 
men who came to be enrolled into the RHDGen study. When they were asked why they 
refused to give their names and sign the consent documents, they explained that they do 
not give their names nor provide their signatures or thumb prints on any documents. In 
such cases, the research nurse or field officer had to document in the consent forms that 
the individuals had agreed verbally to participate in the study.  
From the observations, it was clear that some of the people who refused were gangsters 
and they did not want to put any of their identifiable information on documents. As 
described in chapter 2 above, potential research participants can decide to participate in 
research without necessarily signing informed consent forms. In the Heideveld 
Community, this might have to do with poverty, crime and prison experience as stated in 
chapter 5, section 5.3. This was a unique challenge because the consent documents 
required the names and signatures or thumb prints of the recruited research participants. 
4.3.8 Security and safety of research staff 
The research staff felt insecure during the days of recruitment at the Heideveld 
Community. This was so because of the cases of gangsterism in the community and the 
ongoing gunshots that were heard during the recruitment days. Despite this, the 
community leader assured research staff that they were safe as long as he was present 
at the recruitment site. The community leader knew all the people who were coming for 
recruitment at the site. He himself, also had inscriptions on his arms that were similar to 
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those of the youngsters who were suspected to be gangsters who displayed prison gang 
tattoos. He also exposed signs of wealth, for instance, he had golden teeth and a large 
golden watch. These observations combined with his apparent ability to ensure the safety 
and security of research staff. The feeling of insecurity was an issue among research staff 
who are not used to such unsafe environments and this might have affected the way they 
conducted the recruitment exercise. Some research staff had to ask to be escorted to 
their vehicles upon completion of recruitment on each recruitment day. The issue of safety 
and insecurity among research staff was explored further in the in-depth interviews and 
the results of the interviews are reported in chapter 5, section 5.3 below. 
4.4 Conclusion 
This chapter has attempted to describe the different recruitment contexts and highlighted 
the specific ethical challenges that arose during the consent and recruitment process of 
prospective research participants in the different contexts. From the descriptions, it is 
clear that the different recruitment settings presented different ethical challenges for the 
RHDGen research staff and the research participants themselves. In the successive 
results chapter where findings from in-depth interviews are given, there is detailed 
explanation about the different ethical challenges that emerged in these different settings 
from the research participants’ points of view. 
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5 FINDINGS FROM INDEPTH INTERVIEWS WITH RHDGEN 
RESEARCH PARTICIPANTS 
5.1 DIAGNOSTIC AND THERAPEUTIC MISCONCEPTIONS IN THE 
RHDGEN STUDY 
Diagnostic misconception is defined as failure to appreciate the difference between 
research and diagnosis by research participants [60]. It can also be defined as 
expectations of receiving personal health information as a fringe benefit of health 
research participation [61]. Therapeutic misconception has been extensively studied and 
addressed within clinical trials while diagnostic misconception has been identified as an 
equivalent of therapeutic misconception in the genetic research context [60]. According 
to literature, diagnostic misconception occurs when potential research participants 
consider research participation as an opportunity to be checked or diagnosed for diseases 
[62 - 63]. In some cases, research participants may believe that they are being enrolled 
in research in order to be checked for the disease under study while in other cases, 
research participants may believe that they are being enrolled in research in order to 
receive individualized information about medical diagnoses and future disease risks [60 - 
61, and 64]. This is contrasted with therapeutic misconception that occurs in clinical trials 
when research participants either misunderstand or fail to appreciate the key differences 
between research and clinical care [65 – 66]. Currently, there is not much empirical data 
on diagnostic misconception in genetic studies and none in genomic studies. Therefore, 
this particular finding of this study contributes to the body of literature on diagnostic 
misconception in genomic studies. 
In this chapter, I will seek to demonstrate that most RHDGen research participants had 
beliefs related to diagnostic misconception. These beliefs of diagnostic misconception 
were more common among RHDGen controls than RHDGen cases. 
Most RHDGen controls who participated in the IDIs described that they joined the 
RHDGen study in order to be screened for rheumatic heart disease. They indicated that 
they were interested to be screened for heart disease because this was a free service 
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which was brought to their communities. Most of them mistakenly considered the 
RHDGen study as a screening program for rheumatic heart disease. As witnessed during 
the participant observations, many participants were full of joy and happiness after going 
through the screening program and after being told that they did not have rheumatic heart 
disease. Some came out of the bus with their arms in the air, saying “I have passed the 
test!” The quotation from one of the study participants below supports this finding: 
The thing that motivated me was to know if I have a heart disease and I wanted to see 
my heart beating too (IDI # COV 02). 
Most controls in the IDIs also said that they decided to participate in the RHDGen study 
because the screening for rheumatic heart disease was a free service and that such free 
services were rarely available in their communities. They observed that the Field Officer 
informed them during the introductory talk about the RHDGen study that the screening 
was very expensive in private hospitals and that they considered this as a motivation for 
them to be screened for rheumatic heart disease. For instance, 
I think the other reason is that this is a free service and such free services are rarely found 
here. So, I thought it was necessary to have the service (IDI # COV 04). 
These services are free and they benefit us because they say the scanning of the heart 
is very expensive (IDI # COV 11). 
We don’t have check-ups for heart problems here and sometimes they don’t test our blood 
when we are sick. So, with these free check-ups, I decided to come (IDI # COV 10). 
Most controls recruited at the Heideveld Community also noted that they were requested 
to come for the screening for rheumatic heart disease by their community leader. They 
indicated that the community leader announced to the community that there was going to 
be a free screening program on rheumatic heart disease by doctors from the Groote 
Schuur Hospital. This motivated the community members to come for the screening. Thus 
the research participants said the following: 
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I was asked to come by our chairman. He announced two days ago that doctors from the 
Groote Schuur Hospital will come today and every Monday to screen people for rheumatic 
heart disease. So, that is why I came today (IDI # COH 26). 
The community leader announced to everybody that you would be coming to this 
community to check people for rheumatic heart disease (IDI # COH 32). 
Peer pressure also played a role in motivating some controls to participate in the RHDGen 
study. The control participants explained that they decided to join the study after seeing 
fellow community members participating in the study and that they did not want to be left 
out. The quotation below highlights this: 
It was ok because everybody was being screened for the disease and I didn’t want to be 
left out (IDI # COH 26). 
A majority of controls also said they joined the RHDGen study because they wanted to 
know the conditions of their hearts. They expressed that they made the decision to join 
the RHDGen because they were informed that they would have heart scans and the 
doctor would be able to tell them if they had any heart problems or conditions. The two 
quotations below highlight this finding: 
Hahaha (respondent laughs) I just wanted to check my heart if I had a problem or not (IDI 
# COV 01). 
The main reason why people decided to come is because of the screening for heart 
problems. We were told you had those machines for screening people and since most of 
us do not know whether we have heart problems or not, it was necessary to come for the 
screening (IDI # COH 30). 
An interesting contributory factor lending further support to the importance of the 
diagnostic misconception in the RHDGen enrolment is that many controls also described 
that they joined the RHDGen study because of stories they had heard of people who had 
heart complications and died because of ignorance about the status of their heart 
conditions, for instance, 
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Because another thing that made me get interested, my sister in law died of a heart 
disease. She had a heart problem and so that’s what interested me to know if I have a 
heart problem. I was also scared of passing away from such a disease (IDI # COV 02). 
Some of the controls indicated that they were very happy when they were informed that 
they had no heart problems after the heart scans. In fact, the controls regarded the heart 
scans as an exam or test one had to undergo and they considered it as one of the benefits 
of the RHDGen study as explained by the two controls below, 
I was interested to know if I have a heart problem and I am happy that I don’t have any 
heart problem (IDI # COV 04). 
Yes, it is helpful because people are able to know whether they have a heart problem. 
For me I was happy when the doctor told me that I don’t have any heart problem (IDI with 
study participant # COC 21). 
Some controls also said that they decided to participate in the RHDGen study in order to 
have access to ECHO and ECG services. These services enabled them to have the 
conditions of their hearts checked and some of them were happy to see inside their 
hearts. The quotation below demonstrates this: 
The doctor put something on my chest and I could see my heart moving and he recorded 
everything on that machine. After that, I went to the third room where I could see the 
beating of my heart and the lady there told me that I don’t have any heart problem and 
my heart condition is fine. Obviously, I was happy to hear that because I was worried 
about my heart since I feel pain at the chest at times (IDI # COH 30). 
Some controls were also interested to join the RHDGen study because of their previous 
experience working with researchers in clinical trials and the fact that they also wanted to 
see the echocardiograms of their hearts. Thus two study participants said: 
I was also interested to see the echocardiogram of my heart. Yah I also work with 
pathological specimens and I was curious to see inside of my own heart (IDI # COC 21). 
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Well I work for an organization that runs clinical trials. So, it was quite interesting to be 
the participant and decided to consent and to be informed about this study. I came partly 
because I was quite keen to have an ECHO and an ECG; for me, it was a way of testing 
my heart to see if it was healthy but also I wanted to contribute to science (IDI # COC 20). 
One of the RHDGen research staff who participated in the in-depth interviews noted that 
lack of understanding due to language barriers might have contributed to the 
misconception that the study was a screening program for heart conditions. She also 
observed that some of the participants had already made up their mind to have the 
screening before they went through the consent process and that it was difficult for such 
participants to understand that this was a research activity and not a screening program. 
Thus she said: 
Ok I think the first challenge is probably the language barrier because I don’t speak 
Xhosa. And so, that’s a big challenge to some patients, although they might speak English 
but their English isn’t good. Another challenge is some patients come when they have 
already made up their mind to be screened for heart conditions. So, even when you give 
them information that this is research, they seem not to understand (IDI # RS 02). 
In addition to people joining the study in order to know about their hearts, participants 
also described that they joined in order to know more about their health status. These 
participants indicated that they expected that they would be told the results of their blood 
tests and that the tests would tell them if they had any diseases in their bodies. In fact, 
they regarded the RHDGen study as a general medical check-up and they expected that 
they would receive medical diagnoses at the end of the study. For instance, 
Yaah and any disease they can find in it. In fact I smoke and sometimes I cough. So if 
they find anything in my blood I will be happy to know it (IDI # COH 26). 
As I have said I just wanted to know about health and I am gonna be happy if they want 
to test anything in my blood because I really want to know about my health (IDI # COV 
01). 
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Most of the RHDGen controls also believed that they would be referred to clinicians for 
treatment if they were diagnosed with severe health conditions during the study. This 
belief (misunderstanding) among controls suggests that there is a link between diagnostic 
misconception and therapeutic misconception. Below are quotations from some of the 
controls on this: 
Aah she said if the doctor finds you with a problem, he will give you an appointment to 
see doctors at the hospital. That guy also explained the same. So, I will tell my husband 
to come and that if they find him with a heart problem, he will be given an appointment to 
go to the Groote Schuur Hospital to see doctors for further treatment (IDI # COV 04). 
Yes because if they find you with a problem, they will send you to the hospital to see 
doctors there (IDI # COV 11). 
I think it is both because everybody is checked and if you have the disease, they ask you 
to go to the Groote Schuur Hospital for treatment (IDI # COH 32). 
But it was not altogether wrong because if research participants’ echo were abnormal, 
they were referred to clinicians for treatment and this could be the origin of therapeutic 
misconception. On the issue of diagnostic misconception with regard to taking blood 
samples and performing blood tests, one of the nurses who took part in the IDIs clarified 
that it was not unexpected for the research participants to ask for results of their blood 
tests because they are always provided with results of their blood tests whenever they go 
for clinical care and their blood sample is taken. She said: 
So, usually when they are in the hospital and somebody takes their blood, it’s for a reason 
and they get their results. And now they need to understand that they are giving us blood 
for research purposes and they need to understand that it’s not part of their standard of 
care; it’s only for research (IDI # RS 01). 
Some controls explained that they joined the study because they wanted to know their 
blood pressure. They indicated that their blood pressure is rarely checked and that their 
participation in the RHDGen study provided them with an opportunity to have their blood 
pressure checked. They observed that many people collapse and die of blood pressure 
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because of ignorance about their blood pressure levels. The fear of sudden death 
because of ignorance of their blood pressure levels was a motivating factor for such 
controls. They felt it was important for them to join the study in order to be checked for 
blood pressure since research participants were being checked for blood pressure as one 
of the study procedures. Below are the quotations from the controls on this particular 
finding: 
And the most important thing was to know if I have high blood pressure (IDI # COV 02). 
…I was happy also when the guy told me that my blood pressure is fine (IDI # COV 04). 
I also wanted to know my blood pressure because sometimes you don’t know that you 
have high blood pressure and people do collapse and die because of not knowing that 
they have high blood pressure (IDI # COH 32). 
A majority of the RHDGen cases who participated in the IDIs also stated that they decided 
to join the RHDGen study in order to help find better drugs for treating patients with 
rheumatic heart disease in the future. The research participants noted that the current 
drugs that are being given to patients with rheumatic heart disease such as warfarin can 
have devastating side effects and they felt that through the RHDGen study, doctors and 
scientists would be able to develop better drugs for the current RHD patients and other 
patients in the future. 
Thus the research participants said; 
I think it will also help doctors to come up with new and better medications for this disease 
because they will understand what happens in the body when one has the disease by 
studying the DNA. In such a way, patients with rheumatic heart disease will be treated 
better and other patients with this disease will not have complications in the future (IDI # 
CWR 18). 
Aah I think the issue of finding better drugs for people who suffer from this disease is 
important (IDI # CWR 15). 
As I said they may also develop better medicines to treat the disease (IDI # CWR 18). 
59 
 
I joined because this study is useful. As I said it will help in developing better treatment 
and prevention for people with the sore throat, fever and those with the disease (IDI # 
CWR 15). 
DIAGNOSTIC AND THERAPEUTIC MISCONCEPTION: DISCUSSION 
From the findings of this study, it is evident that the majority of controls chose to 
participate in the RHDGen study because they were motivated by knowledge about heart 
disease, heart conditions, blood pressure, general health status and other medical 
conditions. These beliefs related to diagnostic misconception could be attributed to the 
fact that most of the controls who joined the study were healthy participants who 
considered the RHDGen research participation as an opportunity to be checked for 
various diseases including rheumatic heart disease. This was due to deprivation or limited 
health care access, poverty, unemployment and crime especially among controls that 
were recruited at the Vanguard Community Health Centre and Heideveld community. 
These findings are consistent with findings of an observational bio-specimen research 
conducted among Latino communities on the US-Mexico border by Knerr et al [61]. In 
situations of limited health care, poverty and unemployment, medical diagnoses in 
research settings are described in favourable terms and it is not surprising. In the 
communities where the RHDGen study was conducted, there are health facilities that 
provide free health care, however, the quality of health care is characterized by 
overcrowding and long waiting times. According to Emmanuel, Wendler and Grady, the 
specification and enhancement of potential benefits to individual research participants 
should consider only health-related potential benefits derived from research [67]. In this 
case, participants joined the RHDGen study in order to obtain individual health benefits 
even whilst they acknowledged that this was research and they apparently understood 
that they were participating in research. Although their expectations are related to 
diagnostic misconception, which some may call an “ethical worry” in research 
participation, arguably, it was acceptable for them to enrol in the RHDGen study with 
medical diagnoses as reasons for their participation since they made their decisions 
autonomously.  
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Furthermore, some RHDGen cases reported that the drugs that would be developed from 
this study could help them in improving their own health. Such patients may have 
anticipated that they would derive direct personal benefit in form of better treatment from 
the RHDGen study. This motivation has been described as ‘therapeutic misconception’. 
Therapeutic misconception depicts the hope that research participants may experience 
when previous clinical treatments have failed to help them adequately and hope to obtain 
better treatment by participating in research. Understandably, some patients in the 
RHDGen study have had complications and undergone surgery to implant artificial heart 
valves. Such patients are put on warfarin and they may not have benefitted from penicillin, 
which is the current prophylaxis for rheumatic heart disease. Hence, their hope for a new 
and better drug for rheumatic heart disease is justifiable.  
 
Finally, one needs to appreciate the social context in which these people come from 
before making any judgments. Given the high levels of unemployment, poverty and, 
limited health care in the recruitment contexts, it was arguably not unethical for people to 
choose to participate in the RHDGen study in pursuit of individual health benefits. In fact, 
the participants themselves admitted that they were not forced by anybody to participate 
but chose to take part on their own. In my view, these were rational decisions by the 
research participants. In addition, this was a minimal risk study which did not expose 
participants to excessive discomforts and risks. 
5.2 ALTRUISM IN THE RHDGEN STUDY 
Altruism is defined as loving others as oneself or just as helping others. Auguste Comte 
coined the word altruism in 1851 (www.altruists.org). In Comte’s description, altruism 
means self-sacrifice for the benefit of others. Here, the word “others” can refer to 
members of the general population, fellow community members, friends and family 
members. In fact, evolutionary scientists speculate that altruism has such deep roots in 
human nature because helping and cooperation would promote the survival of our 
species [68]. Indeed, Charles Darwin argued that altruism, which he called sympathy or 
benevolence, is an essential part of the social instincts [69]. Darwin’s claim is supported 
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by some neuroscience studies, which have shown that when people behave altruistically, 
they experience pleasure and reward, similar to when they eat chocolate or have sex [70]. 
In clinical trials, qualitative studies conducted with research participants have 
demonstrated that participants are often altruistically motivated to join clinical trials [71 - 
74 ]. One motivational factor in clinical trials is the desire to help others in the future. For 
instance, a study conducted in India reported that the most common motivation among 
healthy participants was altruism [74]. And a recent qualitative study conducted in South 
London also found that the main reason for research participants to join clinical research 
was believed to be altruism [76]. 
Some research participants in genomic studies have also indicated that they were 
motivated to participate in genomic studies by altruism. In a genomic study conducted in 
Washington DC and Baltimore in the US by Facio and others, it was reported that one of 
the main reasons for participating in genomic research was a conviction to altruism in 
promoting research [77]. In another genomic research also conducted in the US by 
Sanderson and others, it was also found that altruism was one of the reasons for research 
participants’ willingness to participate in genomic research [78]. However, there is a 
dearth of data from empirical research on altruism as a motivating factor for genomic 
participation in Africa. In this section, I will explore the extent to which considerations of 
altruism also motivated participation in the RHDGen study. I am going to demonstrate 
that most research participants decided to join the RHDGen study because of altruistic 
motives. The issue of altruism as a motivation for joining the RHDGen study was more 
common among RHDGen cases than RHDGen controls. 
Most RHDGen research participants who took part in the in-depth interviews described 
that they joined the RHDGen study in order to help other people in future so that they 
might not suffer from heart disease. They indicated that they joined the RHDGen study in 
order to help doctors and scientists in coming up with prevention strategies against the 
development of rheumatic heart disease. Below are the quotations of the research 
participants on this finding; 
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Well, I want to help other people so that they cannot suffer from this disease. In fact, the 
nurse said the study may help other people in the future to be prevented from suffering 
from this disease and I think it is a good idea to help other people not to suffer from this 
disease in the future (IDI # CWR 14). 
Well, rheumatic heart disease is a disease that is affecting quite a good number of people 
and since it is an inherited disease, many more people may suffer from it in the future and 
when I saw the advert, I felt it was important for me to take part in the study so that I might 
help others in the future so that they may not suffer from the disease. That’s what I meant 
when I said it’s for a good cause (IDI # COC 21). 
Whereas for many RHDGen research participants the “others” that their altruism was 
targeted at were not described, some participants linked altruism more directly to their 
family members now and in the future. The research participants observed that they did 
not want their own children and grandchildren to suffer from rheumatic heart disease and 
that they decided to join the study in order to assist doctors and scientists in finding ways 
of preventing the disease from developing prophylaxis which would benefit their own 
children and grandchildren. For instance, 
And at the end, may be it will benefit my own children and grandchildren from not suffering 
from rheumatic heart disease. I don’t want them to go through the suffering I have gone 
through (IDI CWR 29). 
A few RHDGen research participants who took part in the IDIs stated that they joined the 
RHDGen study because of the care shown by researchers. They indicated that they felt 
encouraged by doctors who are conducting further research on rheumatic heart disease 
with the intention of finding better treatment for RHD patients in future. Thus one 
participant said; 
Another thing is that we feel encouraged when we see doctors doing further research on 
this disease because we know that they care about us and they will be able to treat 
patients better in the future (IDI CWNR 23). 
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ALTRUISIM: DISCUSSION 
From the above findings of this study, it is clear that altruism was a motivating factor for 
participation in the RHDGen study. The majority of the research participants were 
motivated by the hope that others would benefit from the development of prophylaxis and 
better drugs for treating rheumatic heart disease which would result from the RHDGen 
study. Some research participants also indicated that they decided to join the study in 
order to help their own children and grandchildren not to develop rheumatic heart disease. 
These findings are consistent with findings of a study conducted among Americans in 
genomic research and a whole-genome sequencing study, both in the US, by Sanderson 
and others [78] as well as Facio and others [77] respectively. These studies found out 
that individual research participants affected with a specific genetic condition reported 
participating in genetic studies for altruistic reasons, for example, to help others who have 
or are at-risk for disease. Similarly, in the RHDGen study, altruism was more common 
among the RHD patients than the healthy volunteers. Of course, it is not surprising for the 
RHDGen cases to have been motivated by altruism to participate in the RHDGen study. 
Historically, the social good and compassion for others, which are characteristics of 
altruism, have been virtues that human beings value. In fact, genetic scientists such as 
William Hamilton have discovered that there are certain genes in humans that are 
associated with altruistic behaviour [68]. Individuals with such genes express sympathy 
and compassion for others and studies have revealed that patients who carry such genes 
do not want others to suffer from the diseases that they have suffered from [79 – 80]. 
Research also suggests that practicing altruism enhances our personal well-being—
emotionally, physically, romantically, and perhaps even financially. It is also necessary 
for  stable and healthy communities as well as the well-being of the human species as a 
whole (http://www.greatergood.berkeley.edu/topic/altruism/definition).More importantly, 
patients feel more compassionate towards their blood relatives including their own 
children as they do not want them to suffer from the pain and suffering they go through 
as a result of diseases which have affected them [69]. Indeed, altruism is part of human 
nature and it plays a role in alleviating the sufferings of others and improving people’s 
health in the world including developing countries such as Africa. 
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5.3 SAFETY AND INSECURITY OF RESEARCH STAFF IN THE RHDGEN 
STUDY 
Research staff play a very vital role in the recruitment of research participants in the field. 
They are an integral part of the research process and they are primarily responsible for 
implementing ‘ethically appropriate’ practices during recruitment in the field [82]. As such, 
any challenges they encounter in the field can affect recruitment and the implementation 
of other study related procedures in the field. As Gikonyo et al and Giessler et al report, 
implicit day to day social relations and engagements during data collection between 
community members and field staff are fundamental to the research process and they 
can impact on recruitment of research participants [37; 83]. 
 
Research staff in the RHDGen study complained about safety and security in one of the 
recruitment sites in Cape Town. Specifically, the issues of security and safety were raised 
at the Heideveld Community where some of the RHDGen controls were recruited. The 
concerns were raised because gunshots were heard during the period of data collection 
and police men were seen patrolling in the community. On the first days of recruitment, 
research staff had to leave the community under cover. Upon inquiring about the 
gunshots and the presence of policemen in the community, it was reported that they had 
to do with gangs in the area. 
 
Gangsterism has been identified as one of the common issues in the urban ghettos of the 
Cape Flats in Cape Town and it is believed to account for almost 70% of all crimes in 
Cape Town [85]. According to Mncube and Madikizela-Madiya, gangs range from 
scavenger types that are involved in petty crimes, territorial types that are well organized 
with initiation rites and to corporate gangs which conduct illicit activities and have distinct 
names and symbols attached to their names [84]. Recently increased gang activities have 
been reported in Manenberg, Delft, Belhar, Hanover Park, Mitchells Plain, Lavender Hill, 
Heideveld and Athlone [81]. Bowers-Du Toit and others have reported that gangsterism 
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is rampant in the Cape Flats because of poverty, un-employment and over-crowding [81]. 
Most gangs are involved in crime and violence as a result of drug and alcohol abuse. 
 
As such, I made an attempt to find out the extent of gangsterism in Heideveld from the 
research participants who participated in the in-depth interviews. My questions centred 
on the impact of gang-related activities to safety and security in the community. 
In this section, I am going to present the responses of the research participants to the 
concerns about safety and security that were related to gangsterism in the community. In 
response to the question about safety and security, most of the research participants 
explained that there was security in the community. When they were probed on why 
gunshots were often heard and policemen were seen patrolling in the community, the 
research participants stated that the gunshots were targeted at members of rival gang 
groups and that the policemen came to the community to provide security because there 
were always fights among the different rival groups of gangsters. They also stated that 
the gangsters trade in illicit drugs and the policemen came to deal with the illicit drug trade 
among the gangsters in the community. For example, one research participant said; 
We have gangs here that fight quite often and most of the gangsters trade and take drugs. 
So, they always shoot each other. That’s why the police always come here. But they don’t 
attack people who are innocent (IDI # COH 26). 
The concerns about safety and insecurity for research staff were also raised by one of 
the research nurses who took part in the IDIs. The research nurse raised the concerns 
because she was part of the research team that was involved in the recruitment of 
research participants at the Heideveld Community. She however observed that she did 
not feel insecure because she was used to working in such environments. The research 
staff said; 
And there was also a concern about security at Heideveld. Some of our staff felt that they 
were not safe to work in that community though I am personally used to working in such 
communities (IDI # RS_02). 
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However, the research participants assured the research staff that there is always 
security in the community. They explained that the gangsters usually attack members of 
their rival groups and strangers who come to the community without their knowledge. 
Thus; 
Yes generally, it is safe. However, sometimes there are these groups of gangsters that 
fight and they usually fight among themselves and sometimes when there are strangers, 
they can also fight them especially if they are not known around here and they don’t know 
why they are here (IDI # COH 30). 
In your case you are not strangers here. Your coming was announced by our community 
leaders and we knew that you were coming. So, there is no way anybody can harm or 
shoot you (IDI # COH 30). 
Yes, you are very safe because they respect Mr. X. They know you are here for our own 
health and they cannot attack you (IDI # COH 26). 
No, no, you don’t have to fear. Mr. X and our leaders are here. So, nobody can harm you. 
You are very safe (IDI # COH 30). 
Aaah if you are not part of the gangsters they cannot attack you. They usually attack each 
other and sometimes they also attack intruders in this community. So, in a way, they also 
protect people who live in this community (IDI # COH 26). 
It’s because the law doesn’t allow people to shoot each other like that and it is illegal to 
trade or take drugs. So, they come here for that (IDI # COH 26) 
The research participants also explained that the gangsters may attack strangers if they 
suspect that they have been sent by the police to spy on them and their illicit trade. They 
also observed that the gangsters provide “protection” to the community by attacking 
people who intrude into the community. For instance; 
Yah they try to protect the community too. Sometimes they are people who come to 
disturb or spy on the gangsters and if they feel threatened they shoot them. You know 
most young people here take and sell drugs and the cops usually come here to catch 
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those youths. So, when a stranger comes, they feel may be he is a spy sent by the cops. 
That’s why they shoot (IDI # COH 30) 
The respondents also revealed that the gangsters use symbols which represent their 
groups and that they are able to identify each other through the symbols. One of the 
respondents said; 
Those are the different symbols the gangsters use to identify each other. In fact, they 
know each through those symbols (IDI # COH 26) 
One of the research participants did not want to name the groups involved in drug dealing 
as gangsters. Instead he explained that the policemen who were seen patrolling in the 
community had come to look for drug dealers. However, the research participant had 
tattoos that resembled those of the gangsters and it is possible that he did not want to 
acknowledge that there were gangsters in the community. He said; 
(Laughs) Yes, this community is safe. There is no problem with security here. Those cops 
come here to look for drug dealers and sometimes they shoot them (IDI # COH 31). 
The research participant observed that the drug dealers earn their living by selling drugs 
and he did not identify the drug dealing as an illicit trade. When the respondent was asked 
if drug dealing was a big problem in the community, he responded; 
Not really, but there are some people who are doing it and they earn a living by selling 
drugs. Otherwise, there is tight security here (IDI # COH 31). 
He also emphasized that the research staff were very safe in the community and that they 
would not be attacked by anybody. For instance; 
But you don’t have to be afraid; nobody can shoot you or attack you (IDI # COH 31) 
Yah, do your work freely because our leaders are all here and nobody can cause 
problems here (IDI # COH 31). 
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SAFETY AND INSECURITY: DISCUSSION 
From the findings of this study, research staff were concerned about the issues of safety 
and security related to gangsterism in the Heideveld Community. The research staff felt 
unsafe and insecure because of the gunshots that were heard during the recruitment 
process. These concerns about safety and security might have affected the consent 
process and other study related procedures. Lack of safety and security could have also 
eroded the morale of research staff. As noted in 4.3.8 above, the research staff were 
assured of safety and security by the community leader and members who were involved 
in the recruitment process. However, as Sassy Molyneux et al have noted, research staff 
need to work in a safe and secure environment in order for them to implement ‘ethically 
appropriate’ practices during recruitment in the field [82]. But for them to feel safe and 
secure, there is need for appropriate engagement with community members and ensuring 
that community members are part and parcel of the research process. For example, 
despite concerns about safety and security during the recruitment of RHDGen research 
participants at the Heideveld Community, research staff were assured that they would be 
safe and secure during data collection in the community because community leaders and 
members were involved in the recruitment process and they were present throughout the 
period of data collection. This ensured the smooth conduct of the RHDGen study in the 
Heideveld Community. 
 
As noted by one of the research staff, familiarity with the recruitment context may also 
help in understanding individuals involved in the research process. For example, the 
understanding that gangsterism was common in the community because of poverty, un-
employment and over-crowding made the research staff to appreciate the day to day 
problems that community members were facing that forced them to resort to crime and 
violence. Understanding that gangs targeted members of rival groups and strangers that 
might have come to spy on the activities of the gangsters also helped research staff to 
feel safe and secure. 
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Finally, community engagement has been identified as an ethical requirement for 
research involving human beings, particularly marginalized populations [11]. It is believed 
that genuine community engagement in community-based research offers the hope of 
enhancing recruitment, safety, security and satisfaction of both research participants and 
research staff [86]. However, I do not know how best community engagement could work 
in the Heideveld Community where gangsterism is very rampant.  
5.4 FEAR OF GIVING BLOOD IN THE RHDGEN STUDY 
Fear of blood is also known as blood phobia and it is defined as the extreme and irrational 
fear of giving blood [87]. People may fear to donate blood to others for blood transfusions 
or they may fear to provide blood for research purposes in biomedical research. This 
section examines reasons why people fear to give their blood samples for use in 
biomedical research and it is informed by in-depth interviews that were conducted with 
research participants recruited into the RHDGen study. 
Previous studies have documented reasons why research participants are afraid of giving 
their blood samples for research purposes [88 – 91]. In a qualitative study conducted in 
Zambia by Zulu and others, it was reported that research participants were afraid to give 
their blood samples in biomedical research because of the belief that the blood could be 
used for satanic practices [88]. Research participants in the study were scared of giving 
their blood samples for research purposes because they had heard rumours in their 
communities that blood drawn during research activities was being used for Satanic 
practices. These beliefs about using blood for Satanic practices in the Zambian context 
are similar to beliefs among Gabonese that blood drawn from research participants is sold 
by medical staff to the Rosicrucian Order, a semi-secret society affiliated with the Free 
Masons of Western Europe and the United States [92]. 
However, in another qualitative study conducted by Boahen and others in Ghana, it was 
reported that research participants feared to give their blood for research purposes 
because of their discontent with the quantity of blood that research participants were 
requested to give [89]. The research participants in the Ghanaian study viewed the blood 
samples being drawn as too much for their liking. In the same Ghanaian study, it was also 
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reported that some research participants did not understand why blood would be drawn 
from healthy people and this was another reason why participants were unwilling to 
provide their blood. Some research participants in the same study had the opinion that 
researchers could use the blood for rituals while others talked about having unpleasant 
experiences following blood draws [89]. 
The fear of pain was also reported as one of the main reasons why research participants 
hesitated to give their blood for research use in an Indian study [90]. And in another study 
conducted among health professionals in India, it was reported that research participants 
had negative attitudes that blood draws could lead to weakness, anaemia and reduced 
immunity [91]. 
Therefore, in this section, I am going to demonstrate that some RHDGen research 
participants had various reasons for fearing to give their blood for study-related tests. 
A majority of the RHDGen research participants who were afraid of giving blood explained 
that they were scared of giving blood samples because they felt that the quantity of blood 
draws was too much. They observed that three (EDTA) tubes of blood samples that were 
being collected from them were a lot and they became scared. For instance; 
It’s just my fear and I think when I saw the nurse taking blood from that other guy, I thought 
it was a lot of blood and I was afraid of that (IDI # COH 26). 
Aah for the blood, I don’t know why the nurse is taking too much blood, perhaps she 
should be explaining to people why she is taking too much blood (IDI # COH 32). 
I was not happy with the amount of blood she took; it’s too much because when we go to 
the hospital, they don’t take much blood as she is doing but I had no courage to ask her 
why she took 3 tubes of blood from me (IDI # COH 31). 
The blood they are drawing is too much. They could reduce it to may be one tube instead 
of the three tubes of blood they are getting from us (IDI #CWR 15). 
On the quantity of the blood draws, the RHDGen cases complained that it was too much 
for them to give such a volume of blood because they were also required to give blood 
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samples for clinical purposes on the same days they were recruited into the RHDGen 
study. The main reason for their fear on the amount of blood draws was that they did not 
have enough blood and they could become anaemic. Below are quotations from the 
research participants on this; 
I think it was too much considering that the doctors also collect blood from us every time 
we come. So, I am afraid that I may become anaemic if I have to give this amount of blood 
every time I come to the hospital (IDI # CWR 18). 
Aah may be the other thing is the blood. I think she took a lot of blood from me and I was 
not happy with that because I can become anaemic. I think they should reduce the amount 
of blood they take from people because it can scare some people from participating in 
this study (IDI # CWR 28). 
I think it is still too much considering that some of us don’t have enough blood (IDI # CWR 
14). 
A good number of RHDGen research participants were afraid to give their blood because 
of concerns they had about the use of left-over blood samples. They explained that they 
heard stories circulating in their communities that some doctors who sell blood to 
Sangomas which they use for muthi. Because of these rumours, the research participants 
suspected that doctors in the RHDGen study could abuse the sell the left-over blood 
samples by selling them to Sangomas. Other research participants stated that community 
members think researchers sell blood to other people without specifying who the other 
people were. The quotations below highlight these; 
Not really, but we always become suspicious when doctors collect a lot of blood from us 
because we don’t know what happens when the blood is left over. Of course, in the past 
I heard about rumours that some doctors were selling blood to Sangomas for muthi (IDI 
# COH 32). 
Eeh they think you are going to sell some blood to other people (IDI # COH 32) 
The speculations about doctors selling blood to Sangomas have not been verified and 
they might be misconceptions that community members have about what happens to left-
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over blood in both clinical and research settings. In this study, we attempted to find out 
examples of cases where doctors were found or caught selling left-over blood samples to 
Sangomas, but none of the research participants who talked about it came up with 
examples. Thus; 
People talk about it but I have never seen a doctor selling blood to Sangomas. May be in 
the past it was happening and that is why people talk about it (IDI # COH 32). 
Some research participants were afraid to give blood because they were afraid of the pain 
that is associated with needle injection when nurses are drawing blood. They observed 
that application of spirit before injecting the needle lessens the pain. One research 
participant said; 
For me she just used cotton and the needle without applying any spirit and maybe that’s 
why I felt pain. I know that when I go to the hospital, they apply spirit and the nurses do it 
gently in such a way that I don’t feel pain. But today the needle was painful and I felt very 
painful (IDI # COH 26). 
On the pain that some research participants felt during the blood draws, they explained 
that the research nurse had difficulty to find the right vein to draw blood from and this 
caused pain to the research participants as the nurse to inject the needle on various veins 
before she could find the right vein to draw the blood from. 
It was painful because she could not find a vein where she could draw blood. So, she 
tried to collect it from different veins and I felt pain (IDI # COH 32). 
As I said the nurse took a lot of blood and felt pain on both arms because she had 
difficulties to get the blood (IDI #CWR 14). 
And I also felt pain when she was taking the blood because she couldn’t find where to 
take the blood. Maybe she couldn’t find the right vein where she could draw the blood. 
She tried on both arms and she has problems to get the blood (IDI # COV 10). 
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Yooh it’s too much and it was painful when she was taking it because she couldn’t find 
the right vein to collect the blood. So, she tried on both of my arms and I am still feeling 
pain (IDI # CWR 18). 
Some research participants stated that they felt blood is life and it is part of them. As such, 
they would not like to give blood for research purposes. They also noted that they would 
not want to share their life with “foreigners” when they were informed that the blood 
samples could be shared with other researchers who would want to do future research. 
One research participant suggested that instead of taking blood, they could get urine or 
saliva and do the tests. They stated that whenever blood is being drawn from them, they 
feel like part of them was being removed. 
For me, I don’t like giving blood. I gave the blood because the nurse said everybody has 
to give the blood. But if it was possible, they could check the disease may be in urine or 
saliva instead of blood because blood is life. (IDI # COH 26). 
My brother as I have said, blood is life and you cannot share it with foreigners because 
these people cannot share their blood with us (IDI # COV 11). 
I just become irritated with it. I feel like a part of me is being removed (IDI # COH 27). 
Some research participants said they did not like giving blood samples. When they were 
quizzed as to why they did not like giving blood, they did not provide any reason. They 
said they were either scared or did not like giving blood at all. For instance; 
I don’t think there are any risks except that personally I don’t like giving blood (IDI # COH 
27). 
Yooh, she took too much blood from me and I didn’t like it (IDI # COV 04). 
Am always scared to have my blood taken (IDI # COH 30). 
Despite their fears, all the RHDGen research participants provided their blood samples 
for the study because they were told that they would be excluded from the study if they 
did not provide blood samples. Since blood draw was one of the final study procedures 
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recruited into the RHDGen study, the research participants felt obliged to provide the 
blood samples despite their fears. Thus 
Yaah I accepted because she said she would not include me if I did not give blood (IDI # 
COH 26). 
I was forced to give the blood because the nurse said I will not be part of the study if I 
refused to give my blood (IDI # COV 13). 
FEAR OF GIVING BLOOD: DISCUSSION 
From the findings of this study, there were various reasons why some RHDGen 
participants were afraid to provide their blood for this study. The reasons included that; 
the quantity of blood draws was too much; they were afraid of becoming anaemic as a 
result of too much blood draws; they had fear that their left-over blood samples would be 
sold to Sangomas for muthi; they were afraid of pain associated with needle injection 
during blood draws; and they had the perception that blood is part of one’s life and cannot 
be removed from someone. 
Consistent with the Ghanaian study and Zambian studies conducted by Boahen and 
others, Zulu and others as well as Kingori and others, RHDGen research participants 
were not happy with the amount of blood that was being collected from them and they 
thought that the left-over blood could be sold to Sangomas who would use it for muthi [88 
-89 and 93]. There was a strong feeling among research participants that there was too 
much blood that was being drawn from them and they thought that it might have been 
done intentionally so that the researchers could sell the left-over blood to traditional 
healers. However, the actual amount of blood which was being drawn was equivalent to 
30 mls in three EDTA tubes of 10 mls each. This amount of blood was just enough for 
carrying out study- related tests. The main reason for the participants’ fears could be 
attributed to the fact that they were able to see their blood in the EDTA tubes and they 
thought it was a lot of blood. 
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In addition, the fear of pain as a result of needle injection during blood draws is also 
consistent with the findings of the study conducted by Uma and others in India [88]. 
However, unlike in the Indian study, in this study the pain came about mostly because of 
the failure of the research nurse to find the right vein where she could draw blood at the 
first attempt. This resulted in the injection of the needle on several parts of the arm that 
might have caused some pain to the research participants. 
Furthermore, similar to the findings of the Indian study conducted by Desai and others, 
the RHDGen research participants were afraid that the perceived excessive blood draws 
could lead to anaemia [91]. This was common among RHDGen cases because they were 
required to provide extra blood samples for routine clinical care on the same days they 
were recruited into the RHDGen study. Perhaps the story would have been different if 
these research participants were recruited on separate days from the clinic days in which 
they had to give extra blood for clinical purposes. 
Moreover, RHDGen research participants observed that blood is life and it is part of one’s 
body. This finding is about the perceptions of most Africans about blood and bodily 
integrity. In most African cultures, blood has a symbolic value and strength as highlighted 
by De Vries and others in their discussion paper [94]. Blood is also considered as a life-
giving force by most Africa cultures as reported in the studies conducted by Grietens and 
others in Gabon [92]. Therefore, it is not surprising that some research participants were 
afraid of providing their blood to the RHDGen research since they consider blood as life 
and part of their body. As one of the research participants observed, giving blood was 
perceived as removing a part of one’s body. 
Finally, to counter all these fears about giving blood for research purposes, there is need 
to provide adequate information to potential research participants about the blood 
samples that are collected from them. Potential research participants need to be 
adequately informed about the purposes for collecting blood samples and how the 
samples are used in research settings. 
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5.5 COMPREHENSION OF INFORMATION ABOUT THE RHDGEN 
STUDY 
Comprehension or understanding of information disclosed during the consent process is 
one of the main elements of valid consent. Potential research participants are required to 
understand information that is provided to them about any study before they make their 
voluntary decision to participate in the study. Research participants’ understanding of the 
study entails that they are aware of the both the benefits and risks of the study as well as 
all the study procedures and what is required of them during their participation in the 
study. However, evidence indicates that research participants often do not fully 
understand the studies for which they have volunteered. Various studies that have 
examined the process of obtaining informed consent for research and participant 
comprehension and satisfaction with the research have reported that there are challenges 
both in the provision of information to potential research participants by research staff and 
in the research participants’ understanding of the disclosed information [35; 45;44; 97; 
41; 50; 95 - 96]. The studies have reported several challenges that affected understanding 
of information that was provided to potential research participants during the consent 
process. One main challenge that affected comprehension of information disclosed to 
potential research participants during the consent process is language [44; 97; 95]. 
Language becomes a hindrance to understanding information about a study by potential 
research participants because some languages lack certain words for scientific terms and 
scientific concepts that are used in research and researchers may fail to translate such 
terms and concepts into the vernacular language spoken by potential research 
participants [35]. For instance, in a study conducted in Ethiopia, Tekola and others 
reported that the language levels used in information sheets and consent forms were not 
comprehensible to potential research participants even after the forms were read to them 
by research staff [44]. Tindana and others have also reported that it becomes difficult in 
genetic and genomic research to explain scientific terms and concepts such as “gene”, 
“genetics”, “genomics”, “DNA”, “genetic database” and “data release” in local language 
during the consent process [41]. They observed that the difficulty in explaining these 
scientific terms and concepts may be compounded by illiteracy in developing countries 
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[41, 46]. Tindana and others also reported that both research participants and research 
staff responsible for obtaining consent did not understand fully the methodologies 
employed during genomic research and their implications [41]. In an empirical study 
conducted in India, Kumar-Patra and Faulkner have demonstrated that the research staff 
did not understand that the data collected during the genetic study could be used in future 
secondary research [45]. In addition, in her discussion paper on informed consent for HIV 
cure research in South Africa, Ciara Staunton has noted that research participants in 
clinical trials do not understand the basic concepts in the informed consent process [96]. 
Staunton raises a concern about therapeutic misconception among future HIV research 
participants due to their failure to understand the basic elements of future clinical trials 
that are aimed at curing HIV/AIDS and confusing such clinical trials with clinical care. 
Marsh and others in Kenya have also reported that field workers in the Kilifi Genetic Birth 
Cohort Study had challenges in explaining genetics and genomics to potential research 
participants [97]. Instead the field workers had to use their own explanations about the 
study without referring to the information sheets which had such scientific terms as 
genetics and genomics. They also emphasized on screening for sickle cell disease more 
than talking about the genomic research [97]. 
In this section, I am going to explain the challenges research staff had in explaining the 
scientific terms and concepts of genetics, DNA and data sharing to potential research 
participants that affected research participants’ understanding of  these terms and 
concepts. I will also explain the difficulties potential research participants had in 
understanding these terms and concepts. Research staff were asked to explain the 
difficulties they had in the disclosure of information to research participants and the 
challenges they had in explaining some of the scientific terms and concepts used in the 
RHDGen study. Research participants were asked to explain what they understood by 
genetics, DNA and data sharing as well as why they would allow data sharing in the 
RHDGen study. 
The RHDGen research staff reported that they had difficulty in explaining genetics and 
data sharing to potential research participants. According to the research staff, some 
potential research participants had never heard of the word “genetics” before and it was 
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taking a lot of time for the research staff to explain it to them. In some cases, research 
participants would still show that they did not understand it even after explaining it to them 
several times. The research staff said the difficulty in explaining data sharing came about 
firstly because some potential research participants did not understand what data meant. 
Secondly, the research participants did not understand that researchers could read their 
information from their blood and let alone that researchers could share data of their 
research participants among themselves. Due to the difficulty in explaining the concept 
of data sharing to potential research participants, the research staff had to take a lot of 
time to explain it with the aid of pictures of a library and with reference to computers. 
However, they were still some research participants that could not understand all the 
information provided to them about genetics and data sharing. For example; 
I think most of our patients have never heard of genetics; it’s a new word to them. And 
the other difficult part of this study is trying to explain to them that some of their bloods 
will go to Canada and other doctors are going to look at them and they can also read their 
information. Yaa that’s something that also takes a bit of time to explain to the patients 
(IDI # RS 01). 
 
Aah first of all they don’t always understand what data is. I have to explain to them that 
what we are reading from them is the information they give us and what we get from their 
blood which doctors want to learn from them and that’s what we call data. And if they 
don’t know what data sharing means, I have also to explain to them. I tell them that like 
computers, everybody can log in and access the computer – I have got pictures of a 
library and it’s like a library where people can access information and share knowledge – 
we share knowledge in the library. But still some participants would not understand all 
this (IDI # RS 01). 
 
The research staff also highlighted that the information leaflet for the RHDGen study had 
explained the concept of data sharing by stating that “it is now common that genetic 
information is shared with researchers around the world and that we would also like to 
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share your genetic information and some of the clinical information with other researchers 
for other projects after we finish our study.” However, they observed that some potential 
research participants kept asking questions as to why their genetic information would be 
shared with other researchers around the world and they would express fears that the 
researchers might decide to clone them and make other people. Much as the research 
staff would try to justify data sharing by stating that it would benefit many researchers 
who might want to use the same information for different research projects and that they 
would not use their blood to clone them, some research participants would not be 
convinced and they would still refuse to have their genetic information shared with other 
researchers around the world. The research staff attributed the research participants’ 
refusal to have their data shared with other researchers to the research participants’ 
misunderstanding of the concept of data sharing.  
 
Some participants refused to have their data shared with other researchers. Of course, 
we had to respect their decision although I think that it had to do with their 
misunderstanding about what I explained to them about data sharing (IDI RS 02). 
Aaah so, when I have gone into the genetics side of the study, I always get questions 
related to the genetic side of things. So, I often get asked the researchers gonna not clone 
me and make other people. You know they are hearing these stories from the movies. 
Yaah I get asked questions about that. And then they also ask more questions about their 
disease and their condition. Can their children catch it from them? You know all those 
general kind of questions and because of not understanding my explanations, they refuse 
to have their data shared (IDI # RS 01). 
We have had very few people, mostly Moslem patients, who refused to have their blood 
sent overseas on religious grounds. It was more of not allowing their blood samples to 
leave the country, they wouldn’t want some of it to leave the country (IDI # RS 01). 
The RHDGen research staff also noted that some research participants lacked 
understanding of the information which was provided to them because of language 
barriers. They noted that some of the Xhosa speaking research participants had difficulty 
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in understanding English and in cases where the research staff who were involved in 
consenting potential research participants did not speak Xhosa, it was difficult for such 
research participants to understand the explanations about genetics, DNA and data 
sharing. Thus; 
Ok I think the first challenge is probably the language barrier because I don’t speak 
Xhosa. And so, that’s a big challenge to some patients, although they might speak English 
but their English isn’t good. Of course, I tried to explain to them what genetics and DNA 
mean. I even spent time to explain to them that their genetic information will be shared 
other researchers in future. But even though I gave them all this information, they seemed 
not to understand (IDI # RS 02). 
Sometimes I had difficulties to explain the study to Xhosa speaking patients because I 
don’t speak Xhosa. Of course, I would try to explain genetics, DNA and data sharing but 
I could still see that they did not understand what I was saying because of the language 
(IDI # RS 01). 
Another challenge was about the difficulty for research participants to understand the link 
between genetics and rheumatic heart disease. The information leaflet had translated 
genetics as “genetic material” or “the building block of our bodies, and that it is information 
that is passed on from one’s mother and father to you, and it is shared between family 
members.” However, it appeared that some healthy controls did not understand why 
genetic tests would be done on their blood. Their (mis)understanding was that genetic 
test would establish whether they had inherited a heart disease from their parents. The 
misunderstanding came about because their blood samples were taken after the 
Cardiologist had already performed ECHOs and ECGs and informed them the results. As 
such, in the in-depth interviews some healthy controls kept asking why the research staff 
were interested in collecting their blood which had the genetic material when they had 
been told that they did not suffer from the rheumatic heart disease. For example; 
My understanding is that genetics is about what we inherit from our parents such as our 
appearances and characters too.  For example, I am coloured because I inherited these 
genes from my parents and I maybe short tempered because I inherited their short 
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temperament from my father. And the sister also explained the same thing. But I don’t 
understand why the sister took my blood to study genetics while the doctor told me that I 
don’t have any heart disease (IDI # COH 27). 
I told the sister that I don’t have this heart disease. So, I don’t know why she decided to 
take my blood and do genetics to see if I have the heart disease when the machine did 
not find it. I don’t really know how they will identify the disease in my blood by doing the 
genetic test (IDI # COV 13). 
The research staff reported that they would not enrol potential research participants if 
they had feelings that they did not understand what the study was about.  After disclosing 
information about the RHDGen study, the research staff would assess the prospective 
research participants’ understanding of the information disclosed and if they were 
convinced that the prospective participants did not understand what the study was about, 
they would repeat the information session until they were convinced that the prospective 
research participants understood it. If after the repetition the prospective research 
participants seemed not to understand what the study was about, they were excluded 
from the study. However, the research staff did not assess prospective research 
participants’ understanding of the scientific concepts and terms of “genetics”, “DNA” and 
“data sharing”. They also observed that there were some patients who would think that 
the research study was part of their routine care and for such patients, the research staff 
would also refuse to enrol such patients into the study. Thus; 
Well, I don’t enrol the patient if I get the feeling that they have no understanding of it 
because often they think it’s part of the care they receive. They are coming to see the 
doctor today and they think it’s just part of that. And I see that they think it’s part of care 
of seeing the doctor and if I find that they think it’s part of seeing the doctor and 
management of the day, then I don’t enrol them. Yaa sometimes it takes me much longer 
to repeat myself to explain to them and I often ask them to repeat what I have explained 
to them. I often ask them what do you understand about what I have just told you about 
what we are doing. And from what they tell me, I will either go over and over again. But if 
I can clearly see that they don’t just understand and think it’s just for the management of 
today, I don’t enrol them (IDI # RS 01). 
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The research staff observed that they had challenges in explaining the RHDGen study to 
research participants because it was a genetic study. They noted that it was time 
consuming to explain the scientific terms and concepts used in genetic studies because 
the terms and concepts were very unfamiliar to most research participants and the 
research staff had to repeat the explanations several times in order to get the message 
across. They acknowledged that this was the most difficult study they had ever 
participated in as far as the explanation of information about the study to research 
participants was concerned. Thus; 
Yaah if I compare it to other research projects I have done before and explaining research 
concepts to research participants, I think the consenting of patients into this genetic study 
has been one of the most difficult and my most consuming time to get the message across 
to the patients, because it takes much longer to explain to the patients and it’s something 
that is unfamiliar to a lot of patients. It’s something they have never heard before. While 
if you are just explaining blood taking or that you are testing a new drug, they have heard 
that before. (IDI # RS 01). 
They recommended that research staff who are involved in recruiting research 
participants in genetic studies need to be provided with adequate training about the 
consent process and the protocol. Below is what they said; 
Well, I definitely think the person taking the consent, the research nurse or the doctor, 
they must be trained in the consent process before they start consenting patients; they 
must have a good understanding of the study and know what they are having to tell the 
patients. Yaah they must have a good understanding of the study because if they don’t 
have a good understanding, how can they explain it to patients. Because I must say I took 
a long time to actually data sharing and what we were really doing with the blood. So, 
Research Staff need adequate training before they can relay any message to patients 
(IDI # RS 01). 
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I think the problem with this study is that we did not have proper training of the protocol 
and the consent process. If we were properly trained and practiced before we started 
recruiting research participants, we would not have faced these problems in explaining 
the study to participants (IDI # RS 02). 
Consistent with what the research staff had said, some research participants reported 
that they had difficulty to understand some of the scientific terms and concepts used in 
the RHDGen study. Thus the research participants said; 
I don’t really know anything about genetics and DNA. The nurse explained them to me 
but these words are very new to me but I don’t I understood clearly what she said (IDI # 
COC 21). 
I have never heard about genetics and DNA. It was my first time to hear about these 
words and I was not attentive when the sister was explaining. So, I cannot remember 
what they mean (IDI # COH 32). 
No, I didn’t understand what she said about DNA. She just said that they are going to do 
DNA tests but she didn’t explain what it means. She also talked about genetics and genes 
but she didn’t explain what genetics, genes are (IDI # COC 20). 
The research participants also disclosed that they did not understand what genetics and 
DNA meant because the research staff did not explain what they meant. They explained 
that the research staff mentioned genetics and genes without defining what they meant. 
They also noted that research staff mentioned that DNA tests would be performed on 
their blood but they did not explain what they meant by DNA. They cautioned research 
staff not assume that potential research participants understand these scientific concepts 
but that they should always explain these scientific concepts and terms to research 
participants. The following quotations highlight this; 
Certainly they have to explain what they mean by genetics and DNA because this is a 
genetics study. There are people who don’t know what genetics or genes mean let alone 
DNA. So, it is not good to take things for granted. The research nurses need to explain 
these things to participants (IDI COC 20). 
84 
 
She didn’t explain what DNA is. She just said that they are going to do DNA tests but she 
didn’t explain what it means. She also talked about genetics and genes but she didn’t 
explain what genetics, genes are (IDI # COV 10). 
Yaah they have to explain in a summary what these terms mean. I know that these terms 
are quite new to some people who have not gone through the high school or college. So, 
explaining them won’t do any harm (IDI # COV 13). 
No, I don’t know genetics and DNA (IDI # COV 01). 
Ooh I can’t remember what DNA means but I learnt it when I was doing Biology. 
Unfortunately, the nurse did not explain it (IDI # COV 04). 
However, some research participants seemed to have understood what DNA and 
genetics meant. They were able to explain in their own words what they understood by 
genetics and DNA and it was clear from their explanations that they had understood what 
the research staff had explained to them about these terms. Some of the research 
participants also explained that they acquired knowledge about these scientific terms and 
concepts from Biology classes at High School while for most patients recruited in the 
Cardiac Clinic, they might have got information about genetics and DNA from clinicians 
during their routine clinical visits. For instance; 
I think I have explained that the DNA has genes which we inherit from our families or 
parents. So, genetics deals with the genes we inherit from our parents. Any child who is 
born shares genes from both the mother and father and this also applies to the diseases 
we inherit from them (IDI # CWR 14). 
DNA and genes have to do with genetics or what we inherit from our fathers and mothers 
(IDI # CWR 18). 
Aaah she said they will check the genetic material in the DNA which is in the blood and 
they will inform us what they will find … DNA is the genetic material that is found in the 
blood. (IDI # COH 26). 
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Genetics is about what we inherit from our parents… I learnt this at school (IDI # COV 
04). 
Genetics is the study about genes in the body. We inherit genes from both our parents 
(IDI # CWR 15). 
Aaah genes are things we are born with in a particular composition I guess which are 
switched on and off as we get old and so that’s what I understand by genes. And some 
people may have a predisposition to rheumatic fever depending on who their parents are 
and the environmental factors under which people are born while others don’t have it. 
Yaah I think genes are found in the DNA and I assume that is why they will do DNA tests 
on the blood (IDI # COC 21). 
According to the biology I did during my O Level studies, genes are found in the blood 
and we inherit some genes from both our father and mother (IDI # COC 03). 
The research participants also reported that they had difficulty to understand the concept 
of data sharing. Their lack of understanding was based on the fact that research staff did 
not explain what it meant and in some cases, it appeared the research participants did 
not pay attention to the explanations that were given by the research staff about data 
sharing. Here is what they said; 
I do not understand what you mean by data sharing…the nurse did not explain what you 
are talking about (IDI # COH 26). 
I don’t know what the nurse was talking about when she mentioned data sharing. It was 
not clear to me why these doctors want to share our information with other researchers. 
This is the first that I am hearing that doctors can share patients’ blood with other doctors 
(IDI #COV 12). 
She mentioned something about it but I did not get it. I think there is no reason for these 
people to share our blood (IDI # CWNR 23). 
Despite the lack of understanding of the concept of data sharing, most research 
participants accepted to have their data shared with other researchers in the world. They 
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expressed that they would not have any problems in sharing their data and noted that 
further research on their data might benefit other people in the future. 
Certainly, I would not have any problems with them sharing my data as long as they would 
do it to continue further research that will benefit other people in future (IDI # COC 20). 
She explained that they share data and blood samples in genetic studies and they do that 
to allow other researchers to use the same data and blood samples in their research. So, 
I told her that I have no problem with that (IDI # COV 03). 
Yes, I don’t have a problem with that because I will not need the blood. They can do 
whatever they want to do with it (IDI #COV 04). 
Of course, there were a few research participants who did not want their data to be used 
for research studies on different diseases from rheumatic heart disease. They pointed out 
that they would rather allow the sharing of their data to researchers who are conducting 
studies on rheumatic heart disease since they would be able to develop better treatment 
that might benefit other patients in future. They also expressed the fear that other 
researchers can use their blood to do studies on sensitive diseases such as HIV/AIDS 
which they cannot consent to. For example; 
No, I wouldn’t allow them to use it for research on other diseases because I provided the 
data and blood specifically for a genetic study on rheumatic fever and I wouldn’t be 
comfortable for them to use my blood for doing let’s say HIV research because this 
genetic study is not related to HIV and HIV is a very sensitive disease (IDI # COC 20). 
I can allow the doctors to share my blood with researchers who are doing other 
researches in rheumatic heart disease. But I can’t allow them to use it for research in 
other diseases. What I want is that doctors or researchers should find better treatment for 
patients who have this disease (IDI #CWR 29). 
Finally, some research participants said that they were not willing to share their data with 
researchers outside South Africa. Their preference was that the blood should be shared 
with South African researchers and their reasoning was that blood is life and it cannot be 
shared with foreigners. They also expressed fears that such researchers could not share 
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their blood with South Africans and they could abuse the blood for their own benefit. Of 
course it is not very clear whether these sentiments were raised by the research 
participants because of their lack of understanding about data sharing although some 
research participants who refused to have their data shared appeared to have understood 
this concept. 
First of all, I will be happy to know where the researchers are because blood is life and 
you cannot share it with anybody even with people who are outside the country because 
these people cannot share their blood with us. I would be comfortable if the blood is 
shared with South African researchers because they are my own brothers and sisters 
who will use it for this country (IDI # COV 03). 
No, I cannot allow them to share it with other researchers or the whole world. I cannot be 
happy to see my data being used by people who are in the UK or Canada. In short, I 
cannot allow researchers from other parts of the world to use my data (IDI #COH 26). 
No, I would not want any other people or doctors or whoever you call researchers to have 
my information. What if they make it public on the internet? I cannot allow them to use my 
information because I don’t know them. I have given my information to the nurse because 
I know that it will be used by doctors here and I know the nurse. I am afraid that some 
doctors I don’t know can use my blood for something else and that’s my worry (IDI #CWR 
28). 
COMPREHENSION: DISCUSSION 
From the findings of this study, it is very clear that research staff had difficulty in explaining 
the scientific concepts and terms of genetics, DNA and data sharing to research 
participants. It is also clear that some research participants had difficulty to understand 
the scientific terms of genetics and DNA as well as the concept of data sharing in genetic 
studies. From the findings of the study, it is also very clear that literacy levels and 
language played an important role in understanding scientific terms of genetics, genes 
and DNA as well as the concept of data sharing. However, it is not very clear whether 
some research participants refused to have their data shared with other researchers 
88 
 
because of their lack of understanding of data sharing though a few of them explained 
the reasons why they refused to have their data shared. 
Similar to the findings of a qualitative study conducted by Marsh and others in Kenya on 
the Kilifi Genetic Birth Cohort Study [97], RHDGen research staff had challenges in 
explaining genetics, DNA and data sharing to potential research participants. As Tindana 
and others have observed [41], research staff might not have understood the scientific 
concepts used in genetic research and their implications which made it more difficult for 
them to explain the concepts comprehensively to potential research participants. 
Although the information leaflet of the RHDGen study provided simple explanations of 
genetics, DNA and data sharing, it was still a challenge for the research staff to explain 
the concepts to the research participants. In fact, the research staff themselves 
acknowledged that this genetic study was one of the most difficult studies to explain to 
research participants. Of course I do not agree that protocol training and training in the 
consent process would have improved manner in which research information was 
provided to potential research participants and enhance research participants’ 
understanding of the disclosed information. I feel there is need to do further empirical 
research to understand why research staff find it difficult to explain scientific terms and 
concepts of genetics, DNA and data sharing to potential research participants despite the 
fact these terms and concepts are explained in lay language in study information sheets. 
There is also need to investigate why some research participants are not willing to share 
their data with other researchers in genetic studies – I am of the opinion that there might 
be some other reasons why some research participants might refuse to share their data 
with other researchers outside their country and these need to be unearthed through 
empirical studies which aim at understanding community members’ perceptions and 
attitudes towards genetic studies. As Tindana et al have suggested, it is important for 
researchers to understand the cultural sensitivities surrounding data sharing and to try to 
find better ways of explaining data sharing as well as obtaining culturally appropriate 
consent for the exportation and sharing of data [98]. Denny et al have also recommended 
that the disclosure of information about data sharing should include information about the 
possible benefits and harms of data sharing to potential participants so that participants 
who give their consent to have their data shared make informed decisions [100]. Indeed, 
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as Parker and Bull report, calls for data sharing should be supported by explanations of 
potential benefits of such sharing to the participants who provide the data and their 
communities [99].  
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6 DISCUSSION OF THE FINDINGS 
When this project was conceived, there was virtually no published empirical work 
describing ethical challenges in obtaining informed consent for health research in South 
Africa in general, and for genomic research in particular. Therefore, this study was the 
first study that attempted to understand the ethical challenges in obtaining informed 
consent in genomic research in the South African context. Specifically, this study has 
attempted to understand ethical challenges in obtaining informed consent in the RHDGen 
study. It explored what research participants understood during the consent process into 
the RHDGen study and it identified factors that could compromise voluntary decision-
making for research participants in the RHDGen study. In-depth interviews and participant 
observations were conducted with research staff and research participants in the 
RHDGen research project in order to understand these issues and specific ethical 
challenges in obtaining informed consent in the different recruitment contexts. A total of 
34 in-depth interviews and 57 POs were conducted with RHDGen research staff, RHD 
patients and RHDGen healthy population controls.  
One major finding of this study was that most healthy controls recruited at the Vanguard 
Community Health Centre, the Heideveld Community and the Clinical Research Centre 
of the Groote Schuur Hospital decided to participate in the RHDGen study in order to be 
screened for heart conditions. In the ethics literature, this concept is called diagnostic 
misconception and it is defined as failure to appreciate the difference between research 
and diagnosis by research participants [60]. It is also defined as expectations of receiving 
personal health information as a fringe benefit of health research participation by research 
participants [61]. RHDGen research participants considered their participation in the 
RHDGen study as an opportunity to be diagnosed for heart diseases and they thought 
this study was a screening program for heart diseases. This has been the first study to 
report diagnostic misconception among research participants in Africa and in South Africa 
in particular. According to this finding, the RHDGen healthy controls were motivated by 
knowledge about heart disease, heart conditions, blood pressure, general health status 
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and other medical conditions. These beliefs among the research participants could be 
attributed to the fact that most of the controls who were recruited into the RHDGen study 
were healthy research participants who considered their research participation as an 
opportunity to be screened for various health conditions. They may have had these beliefs 
due to deprivation or limited health care access, poverty and unemployment as well as 
the fact that these free screening services were not readily available in their communities. 
In situations of limited health care, poverty and unemployment, ancillary care that is 
provided to research participants during their participation in research is described as the 
best treatment by research participants. Because of the generally good health treatment 
they receive during research participation, most research participants who are patients in 
resource limited settings do not refuse to participate in biomedical research. In the case 
of the RHDGen study, the research participants accepted to join the study in order to be 
scanned for heart conditions and be referred for specialist treatment free of charge if they 
were found to have heart problems. Although some of the study participants were 
identified by their community leader and his assistants as potential participants for the 
RHDGen study, they were free to refuse to participate in the study after being provided 
with detailed information about the study by the RHDGen staff who obtained their 
individual written consent. The same was true for potential research participants that were 
provided with information by the field officer at the Vanguard Community Health Centre 
prior to the consent process into the RHDGen study. In fact, some of such potential 
participants decided to leave the recruitment site when they felt that the study procedures 
were taking too long. However, most of those who accepted to join the study did so 
because they wanted to know their heart conditions. In my opinion, the research 
participants were not unduly induced to participate in the RHDGen study. Instead, they 
made their rational and autonomous decisions to participate in the study because they 
wanted to be screened for heart conditions. For example, in the communities where the 
RHDGen study was conducted, there are health facilities that provide free health care, 
however, the quality of health care is characterized by overcrowding and long waiting 
times. According to Emmanuel, Wendler and Grady, the specification and enhancement 
of potential benefits to individual research participants should consider only health-related 
potential benefits derived from research [67]. In this case, research participants joined the 
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RHDGen study in order to obtain individual health benefits although they acknowledged 
that this was research and they apparently understood that they were participating in 
research. Though their expectations are related to diagnostic misconception, arguably, it 
was acceptable for them to enrol in the RHDGen study with medical diagnoses and 
specialist treatment as reasons for their participation since they made their decisions 
autonomously. In my opinion, diagnostic misconception in this particular context was not 
an ‘ethically worrisome undue inducement’ to the research participants because these 
were good decisions made by the research participants and the RHDGen study did not 
expose them to any “unreasonable risks’ [101]. 
Additionally, some RHDGen cases recruited in the Cardiac Clinic at the Groote Schuur 
Hospital reported an expectation that the drugs that would be developed from this study 
could help them in improving their own health. Other patients anticipated that they would 
derive direct personal benefit in the form of better treatment from the drugs that would be 
developed from the results of the RHDGen study. The expectation to receive better 
treatment because of their participation in the RHDGen study has been described as 
‘therapeutic misconception’ in the ethics literature. Therapeutic misconception depicts the 
hope that research participants may experience when previous clinical treatments have 
failed to help them adequately and hope to obtain better treatment by participating in 
research [77]. Nobile et al have identified diagnostic misconception as an equivalent of 
therapeutic misconception in the genetic research context [62]. Understandably, some 
patients in the RHDGen study have had complications and undergone surgery to implant 
artificial heart valves. Such patients might have thought that they would benefit from drugs 
or any interventions that would be developed from the results of the RHDGen study. To 
further understand why both healthy controls and patients recruited in the RHDGen study 
were motivated by diagnostic misconception and therapeutic misconception respectively, 
one needs to appreciate the social context from whence participants came. Indeed, due 
to the high levels of unemployment, poverty and limited health care in the recruitment 
contexts, it was rational for people to choose to participate in the RHDGen study in pursuit 
of individual health benefits. They made rational decisions because screening services 
for heart problems are not readily available in their communities and participants who 
were diagnosed with heart problems were referred to their nearest health facilities and 
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the Groote Schuur Hospital for treatment. As such, it was ethical for them to decide to 
participate in the RHDGen study in order to access such free services.  Whether the 
research participants were adequately informed about the RHDGen study or not, they 
made their voluntary and autonomous decisions to participate in the RHDGen study and 
their decisions were rational and acceptable in the circumstances. Moreover, the research 
participants themselves admitted that they were not forced by anybody to participate in 
the RHDGen study but chose to take part on their own after being motivated by the free 
screening services for heart problems and referral for treatment. In my view, these were 
rational decisions made by the research participants and both diagnostic misconception 
and therapeutic misconception in this context could not be classified as “undue 
inducements” [102]. Therefore, the consent to participate in the RHDGen study, though 
given in the context of diagnostic misconception and therapeutic misconception, was 
genuine.  
Another major finding of this study was that some research staff felt unsafe and insecure 
at the Heideveld Community where some healthy controls were enrolled. The issues of 
safety and security in this community were related to gangsterism that is prevalent in the 
Heideveld Community. I described how concerns about safety and security impacted on 
the consent process and other study related procedures for healthy controls recruited in 
this community. The concerns about safety and security also eroded the morale of 
research staff and in some cases research staff had to conduct the study procedures 
hurriedly in order to do away with the gangsters who had come for recruitment. Although 
the research staff were assured of safety and security by the community leaders and 
members who were involved in the recruitment process, it was evident that research staff 
were affected by these concerns. As Sassy Molyneux et al have noted, research staff 
need to work in a safe and secure environment in order for them to implement ‘ethically 
appropriate’ practices during recruitment in the field [82] and they have recommended 
that appropriate engagement with community members should be undertaken to ensure 
that community members are part and parcel of the research process in cases where 
research staff feel insecure and unsafe. Community engagement has been identified as 
an ethical requirement for research involving human beings, particularly marginalized 
populations [11]. In fact, it is believed that genuine community engagement in community-
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based research offers opportunities for enhancing recruitment, safety, security and 
satisfaction of both research participants and research staff [86]. However, for the 
Heideveld Community, community leaders were engaged through consultation and 
involvement in the recruitment process. Community leaders also assured research staff 
that they would be safe and secure during data collection in the community and the 
community leaders were present throughout the period of data collection. Nevertheless, 
the research staff did not feel secure and safe during the conduct of the RHDGen study 
due to gangsterism. One wonders how best community engagement should have been 
conducted in such a hostile environment. Could familiarity with the recruitment context as 
noted by one of the research staff help in understanding individuals involved in the 
research process? It was of course reassuring to research staff when they were informed 
that gangs targeted members of rival groups and strangers that might have come to spy 
on the activities of the gangsters. Apparently, the gangsters were aware that the research 
staff had come to the Heideveld Community to conduct health related activities and it was 
very unlikely that they could attack the research staff. Despite all this, research staff did 
not feel safe and secure because of the gunshots that were heard and the hostility of the 
environment. Perhaps there is need to find other strategies for engaging community 
members in such hostile environments as the Heideveld Community. One suggestion is 
to sensitize community members about such research activities prior to recruitment and 
request those who are interested to participate to come to the nearest health facility for 
recruitment instead of conducting the research activities within the community. 
The third major finding of this study was about challenges to do with comprehension of 
research information disclosed to potential research participants by research staff. Some 
research participants had difficulty in understanding genetics, genomics, DNA and data 
sharing. Some research participants had difficulty in understanding genetics, genomics, 
DNA and data sharing. There were various possible reasons that could be attributed to 
their lack of understanding of the above scientific terms and concepts. One reason could 
be that they had low levels of education. Educational levels may have played an important 
role in research participants’ understanding of the scientific terms of genetics, genes and 
DNA as well as the concept of data sharing because it was observed during the consent 
process that potential research participants who had high levels of literacy were able to 
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understand the concepts of genetics and DNA from their previous biology studies. 
Another reason could that the scientific terms and concepts used in genetic and genomic 
research were quite new to them. In fact, the research staff also acknowledged the 
difficulty in explaining the scientific terms and concepts to potential research participants 
because the terms and concepts were new to them as well. In addition, previous studies 
have reported research staff’s difficulties in explaining scientific terms and concepts of 
genetics, DNA and data sharing to potential research participants [97; 41]. In fact, in the 
RHDGen study, research staff themselves acknowledged that this genetic study was one 
of the most difficult studies to explain to research participants. Indeed, genetic and 
genomic studies present new scientific terms and concepts that are difficult to explain to 
potential research participants and this calls for research staff to be creative when they 
are explaining such terms and concepts to potential research participants. The use of 
pictures and analogies could help in explaining such terms and concepts to potential 
research participants. Nevertheless, there is need to do further empirical research to 
understand why research staff find it difficult to explain scientific terms and concepts of 
genetics, DNA and data sharing to potential research participants despite the fact that 
these terms and concepts are explained in lay language in study information sheets.  
From the findings of this study, some research participants were not willing to share their 
data and samples with other researchers. Various reasons were given for their 
unwillingness to share their data and samples. Some research participants expressed 
fears that other researchers could use their blood samples to do sensitive studies such 
as HIV/AIDS which they had not consented to. Other research participants refused to 
share their blood and data with other researchers because they said that blood is life and 
that it should not be shared with foreign researchers. They also expressed fears that such 
researchers could not share their blood with South Africans and they could abuse the 
blood for their own benefit. Of course it is not very clear whether these sentiments were 
raised by the research participants because of their lack of understanding about data 
sharing although some research participants who refused to have their data shared 
appeared to have understood this concept. There were still other research participants 
who thought that the other researchers might sell their blood samples to Sangomas 
(traditional healers) and Satanists. Though these rumours have not been validated, there 
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have been raised before by research participants in biomedical research. The other 
reasons given by the research participants for their refusal to share their blood samples 
and data were that researchers from developed countries do not share their data and 
samples with researchers from developing countries.  
Related to the finding on comprehension is the issue of research staff’s pressure during 
the recruitment process at the Vanguard Community Health Centre. Based on the 
observations, research staff were under pressure to recruit prospective research 
participants especially at the Vanguard Community Health Centre. This was due to the 
fact that prospective research participants would come in large numbers and queue for 
recruitment at the site and they were very eager to go through the recruitment process so 
that they would go back to the clinic to see clinicians for their health care. Due to this 
pressure, research staff who were involved in the consent process had to do it hurriedly 
so that they would not miss any of the prospective research participants. This might have 
impacted on the disclosure of sufficient information to prospective research participants 
and it might have affected prospective research participants’ understanding of the 
information. 
Another finding based on the observations was that there was a breach of privacy and 
confidentiality during the consent process in the van at the Vanguard Community Health 
Centre and the Heideveld Community. This breach of privacy and confidentiality 
happened because the consent process and collection of personal information from 
prospective research participants were conducted in the presence of other potential 
research participants. In fact, the van did not provide the physical space that would 
respect privacy and confidentiality of potential research participants.  
The fifth finding of this study was that the majority of RHD patients decided to join the 
RHDGen study in order to help future patients suffering from rheumatic heart disease. 
Most research participants noted that the prevention measures and other drugs that 
would be developed from the results of the RHDGen study could help other patients 
suffering from this disease in the future. The hope for development of prophylaxis and 
better drugs for future patients suffering from a particular disease is a common 
phenomenon among patients participating in biomedical research and genetic studies in 
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particular [77, 78, 103]. Patients who participate in research are often influenced by 
altruistic motives when they agree to join research studies. Most patients do not like 
seeing others suffering from the same disease they have suffered from and they are 
always willing to help others who have or are at-risk of developing the disease under 
study by accepting to participate in studies that may develop better treatment for future 
patients [79 - 80]. This is due to the compassionate nature of human beings and it is not 
surprising that some of the RHDGen research participants especially the RHD patients 
who were recruited in the Cardiac Clinic decided to participate in the study due to altruistic 
motives. Altruism implies that the research participants were not induced to participate in 
the RHDGen study but that they made their own voluntary decisions to participate in the 
study out of compassion for others [101]. Of course, one could observe that the 
motivations for participation such as diagnostic misconception and therapeutic 
misconception, which are self-interested benefits, may be incompatible with altruism, 
which is a collective benefit. However, this study is not unique in reporting these 
incompatible findings since these may exist and be real to individual research participants 
as previously reported by Sikweyiya and Jewkes [103]. 
The final finding of this study was that some research participants were scared of giving 
blood. There was a strong feeling among some RHDGen research participants that there 
was too much blood that was being drawn from them and they thought that it might have 
been done intentionally so that the researchers could sell the left-over blood to traditional 
healers. However, this was just a misconception about the use of blood that was being 
drawn from the research participants. Perhaps the research staff did not explain clearly 
to the research participants the amount of blood that was being collected and why the 
blood that was collected was to be used for. Some research participants were afraid to 
give their blood because of the pain that would result from needle injection during blood 
draws. Indeed, few research participants complained about pain during the blood draws 
but this was due to failure of the research nurses to find the right vein where they could 
draw blood at the first attempt and as a result, they injected the needle on several parts 
of the arm that might have caused some pain to the research participants. Other research 
participants were afraid of the blood draws because of their perception that excessive 
blood draws could lead to anaemia. The fear of developing anaemia from excessive blood 
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draws was more common among RHDGen cases than RHDGen controls because they 
were required to provide extra blood samples for routine clinical care on the same days 
they were recruited into the RHDGen study. Perhaps the story would have been different 
if the RHDGen cases were recruited on separate days from the clinic days in which they 
had to give extra blood for clinical purposes. Moreover, RHDGen research participants 
observed that blood is life and it is part of one’s body. This finding is about the perceptions 
of most Africans about blood and bodily integrity. In most African cultures, blood has a 
symbolic value and strength as highlighted by De Vries and others in their discussion 
paper [94]. Blood is also considered as a life-giving force by most Africa cultures as 
reported in the studies conducted by Grietens and others in Gabon [92]. Therefore, it is 
not surprising that some research participants were afraid of providing their blood to the 
RHDGen research since they consider blood as life and part of their body. As one of the 
research participants observed, giving blood was perceived as removing a part of one’s 
body. The fears in giving blood were also evident during the observations. These fears 
led to some research participants to withdraw from enrolment into the RHDGen study 
although they had already provided their consent to join the study and had already gone 
through the other study-related procedures. To counter all these fears about giving blood 
for research purposes, there is need to provide adequate information to potential research 
participants about the blood samples that are collected from them. Potential research 
participants need to be adequately informed about the purposes for collecting blood 
samples and how the samples are used in research settings.  
 
7 CONCLUSION AND RECOMMENDATIONS 
Based on the information which was obtained from participant observations during the 
recruitment process of both RHD cases and controls as well as in-depth interviews with 
RHDGen cases, controls and research staff involved in obtaining informed consent from 
the research participants, the following are conclusions on the ethical challenges in 
obtaining informed consent from the RHDGen research participants: 
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●Most RHDGen controls had beliefs related to diagnostic misconception. These research 
participants joined the RHDGen study in order to be screened for heart conditions and 
they mistakenly considered the RHDGen study as a free screening program for heart 
conditions.  
●Some RHDGen cases joined the RHDGen study because of therapeutic misconception. 
Such cases anticipated that drugs would be developed from this study that could help 
them in improving their own health. 
●Most RHDGen participants decided to join the RHDGen study because of altruistic 
motives. Altruism as a motivating factor for joining the RHDGen study was more common 
among RHDGen cases than RHDGen controls. The research participants described that 
they joined the RHDGen study in order to help other people in future so that they might 
not suffer from heart disease.  
●Most RHDGen research staff were concerned about the issues of safety and insecurity 
related to gangsterism at one of the recruitment sites. The research staff felt that they 
were unsafe and insecure at the Heideveld Community in the Cape Flats where some 
RHDGen controls were recruited. These concerns might have affected how they obtained 
consent from research participants in this community in that they administered the 
consent process in fear. In fact, the environment at the Heideveld Community was so 
hostile for conducting an ethical study. However, the research staff tried their best to 
conduct the study ethically.   
●Some RHDGen research participants were scared of giving blood for study-related 
activities. Some research participants were afraid of giving the blood because they felt 
that the quantity of blood draws was too much while other research participants had 
concerns about the use of left-over blood samples and the pain associated with needle 
injection.  
●Some RHDGen cases had trust in clinicians who were part of the RHDGen research 
team because of their familiarity with them in the Cardiac Clinic. Because of their trust, 
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they did not pay much attention to the disclosure of study information and they willingly 
consented to participate into the RHDGen study. 
●Some RHDGen controls were familiar with the RHDGen field officer who was 
responsible for providing information to potential research participants and recruiting them 
into the RHDGen study. Some knew the field officer personally while others used to see 
him in their community. Because of their familiarity with him, they willingly presented 
themselves to the Van for recruitment.  
●There was a potential breach of privacy and confidentiality for RHDGen controls who 
were recruited in the van at the Vanguard Community Health Centre and the Heideveld 
Community. The van which was used for recruitment at the two sites did not provide 
adequate space that would respect privacy and confidentiality for research participants. 
This was due to the limited space which was available for conducting study-related 
activities in the two sites. 
●Some RHDGen research participants had difficulty in understanding scientific terms and 
concepts of genomics, DNA and data sharing. 
●Research staff had difficulty to explain the scientific terms and concepts of genetics, 
genomics, DNA and data sharing to potential research participants. The research staff 
noted that it was time consuming to explain these terms and concepts to potential 
research participants because they were very unfamiliar to most research participants.  
 
Recommendations: 
Based on the above findings, I would like to recommend the following to researchers who 
are conducting genomic research in limited resource settings; 
●Research Staff who are involved in recruiting potential research participants for genomic 
studies must be creative during the recruitment process and ensure that the studies are 
conducted properly without compromising ethics. Consent processes must be flexible 
enough to allow staff to adjust these to the specific recruitment context. Staff must ensure 
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that they respect their potential research participants and the decisions they make without 
being judgemental.  
●The design of consent forms for genomic research should not be based on checklists 
for consent documents but they must be informed by experiences of researchers working 
in communities where the intended research projects are to be conducted. For instance, 
consent documents for recruiting potential research participants from communities that 
are unsafe and insecure for research staff must be informed by inputs from community 
leaders and researchers who have experience in conducting research in such 
communities.   
●There is need for genomic researchers to involve potential research participants and 
their communities in sensitization activities where they have to explain scientific terms 
and concepts used in genomic research and allow them to ask questions before 
approaching individuals to take part in their genomic research projects. Such community 
engagement has to involve community leaders as well. And in communities where 
community advisory boards (CABs) exist, CAB members should be involved in 
communicating scientific terms and concepts in lay terms to their fellow community 
members. In communities where CABs do not exist, it is important to establish CABs to 
assist research staff in sensitization activities and communicating information about 
genomics, DNA and data sharing to community members prior to approaching individual 
potential research participants to join genomic studies. 
●When researchers intend to conduct their research among members of communities 
where safety and security issues are a concern, they must ensure that they conduct their 
research activities at health facilities in which such communities fall.  
●Researchers who conduct hospital based studies must ensure that they enrol patients 
into their studies on separate days from the clinic days in order to ensure that potential 
research participants have ample time to go through the recruitment and study 
procedures.  
●In research studies which involve embedded ethicists as researchers within the research 
projects, there is need to clarify the roles of the embedded ethicists in the entire research 
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process and assure research staff involved in recruiting potential research participants of 
the necessity to collaborate with the embedded ethicists in ensuring that the research 
projects are being conducted ethically.  
●There is need for provision of adequate information about research objectives and 
procedures including anticipated benefits and risks to potential research participants 
before obtaining their consent to participate in genomic studies. There is also need to 
assess potential research participants’ understanding or comprehension about scientific 
terms and concepts used in genomic research prior to enrolling potential research 
participants in genomic studies. 
●Finally, it is necessary to train research staff responsible for recruiting research 
participants in the protocol and the informed consent process before initiating genomic 
research projects. After such protocol and informed consent process training, research 
staff should conduct pre-testing (piloting) of data collection tools and informed consent 
documents among lay community members and make appropriate corrections or 
revisions to the data collection tools and informed consent documents before 
implementing genomic studies.  
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9 APPENDICES 
 
Appendix I: Information Sheet and Consent Form for RHDGen Adult Cases and 
Controls Participating in IDIs  
 
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina de Vries  
Introduction  
We invite you to participate in a study. This consent form explains the research study you 
are being asked to join. Please, read it carefully and ask any questions about the study 
before you agree to join. You may also ask questions at any time after joining the study. 
If you agree to participate, our interview will be recorded and written down. The interview 
will be anonymised and nobody except the researchers will know what you said. If we 
report on this study, we may use one of your sentences but even if we do that we will not 
put your name; nobody will know that it was you who said it.  
Purpose of the study 
The purpose of this study is to understand ethical challenges in obtaining informed 
consent for the study on rheumatic heart disease that you joined. We hope to use the 
findings of this study to explore possible interventions for improving ethical challenges in 
obtaining informed consent in genomic research 
Participants 
For this study, we hope to talk to patients with rheumatic heart disease and people who 
do not have the disease who were recruited into the RHDGen research project. We will 
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also talk to research staff who are involved in the recruitment of study participants in the 
RHDGen research project at the Groote Schuur Hospital and in communities within Cape 
Town. We are asking you to participate in an interview of the study on rheumatic heart 
disease that you participated in.  
If you agree to participate, we would like to hear your views about the informed consent 
process: what you understood during the consent process, what you think about the 
consent process, and how best you would like it to be done. We would also like to know 
your understanding of genetics. The interview will last about 60 minutes. It will be 
conducted either in English by Mr. Francis Masiye or in your local language by a Research 
Assistant. It will be recorded as this will help us to focus on what you say to us. The 
recordings will be written down after which they will be destroyed. At the end of this study, 
we would like to keep the transcript of the interview with you. The transcript will be 
anonymous and nobody will know that it was you who was in the interview.  
 
Risks/Discomforts 
There are no physical risks in this study. However, you might feel upset or worried to 
reveal your personal information when answering some of the questions. To minimize 
this, please, feel free to choose not to answer any questions you do not want to answer. 
The interview will take about 60 minutes of your time. 
Anticipated Benefits 
If you decide to participate in this study, you will receive no direct benefits from answering 
our questions. However, your contribution may help researchers better understand the 
challenges in obtaining informed consent in the RHDGen study. We hope that this study 
will help us to improve the current consent process for genomic and genetic studies.  
Confidentiality 
We will keep what you say to us in the interview strictly confidential. You will be assigned 
a unique identification number. We will only refer to the number in future and not to your 
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name. The information collected will be kept in restricted access offices and on password-
secured computers. The recording of the interview and transcript will be kept until the end 
of the study. When we report on our findings, we may use some of the sentences that 
you said. If we use one of your sentences, it will appear together with your unique 
identification number for the interview (for instance, IDI#18). We also ask you to keep 
what we discuss in the interview private.  
Voluntariness and the right to withdraw 
Your participation in this study is entirely voluntary, and there are no consequences if you 
decide not to participate. If a question makes you uncomfortable and you don’t want to 
answer it, then you don’t have to. If during the interview or at a later date you have second 
thoughts, then please feel free to withdraw from the study and if you do we will not 
consider what you said during the interview. Please, feel free to ask me any questions 
you may have about this research study.  
Compensation 
In order to thank you for your time, and to compensate you for any expenses, we will give 
you R150.  
Contact Information 
If you would like more information about this research project before deciding to 
participate, and if you have questions or comments, please contact Mr. Francis Masiye, 
at any time on the following telephone number; 021 650 1902 and he will answer your 
questions. You can also contact Jantina de Vries at 021 650 5716 or Bongani Mayosi at 
021 406 6200.If you have concerns about your rights because you think you have not 
been treated fairly or think you have been hurt by joining the study, you can contact the 
Human Research Ethics Committee in the Faculty of Health Sciences at the University of 
Cape Town on 021 406 6338 or write to Shuretta Thomas, Human Research Ethics 
Committee, Room E52-24, Old Main Building, Groote Schuur Hospital, OBSERVATORY 
7925.  
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Signature 
Have you been provided with sufficient information about the study?   Yes         No  
 
Have you had an opportunity to ask questions and discuss this study?  Yes        No 
 
Have you received satisfactory answers to all your questions?          Yes          No 
Do you understand that your participation is voluntary, and that you are free to withdraw 
from the study at any time? 
                                                                                                            Yes             No 
 
Do you agree to take part in this study?                                              Yes             No 
 
Do you agree to be audio-recorded during the interview?                   Yes           No 
 
Signature………………………………………………..Date…………………………. 
Name of Study Participant…………………………………………………………….. 
Student Investigator/Research Assistant Statement 
I confirm that I have carefully explained the proposed study to the participant. 
Signature…………………………………………….…. Date…………………………. 
Name of Person Obtaining Consent………………………………………… 
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Appendix II: Information Sheet and Consent Form for RHDGen Research Staff 
Participating in IDIs  
 
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina de Vries  
Introduction  
We invite you to participate in a study. This consent form explains the research study you 
are being asked to join. Please, read it carefully and ask any questions about the study 
before you agree to join. You may also ask questions at any time after joining the study. 
If you agree to participate, our discussion will be recorded and written down. The interview 
will be anonymised and nobody except the researchers will know what you said. If we 
report on this study, we may use one of your sentences but even if we do that we will not 
put your name; nobody will know that it was you who said it.  
Purpose of the study 
The purpose of this study is to understand ethical challenges in obtaining informed 
consent for the genomic epidemiological study on rheumatic heart disease you are 
involved in as a Research Staff. We hope to use the findings of this study to explore 
possible interventions for improving ethical challenges in obtaining valid informed consent 
in genomic research 
Participants 
For this study, we hope to talk to adult cases and healthy population controls who have 
been recruited into the RHDGen research project and research staff who are involved in 
119 
 
the recruitment of study participants in the RHDGen research project at the Groote 
Schuur Hospital and in communities within Cape Town.  
We will interview 4 of you who are involved in the recruitment of research participants into 
the RHDGen research project. If you agree to participate, we would like to hear your views 
about the informed consent process: the challenges you encounter during the consent 
process, what you think should be done in order to improve the consent process. The 
interview will last about 60 minutes. The interview will be conducted in English by Francis 
Masiye, who is the Student Investigator. It will be recorded as this will help us to focus on 
what you say. The recordings will be transcribed verbatim. At the end of this study, we 
would like to keep the transcript of the interview with you. The transcript will be 
anonymous and nobody will know that it was you who was in the interview.  
Risks/Discomforts 
There are no physical risks in this study. However, you might feel upset or worried to 
reveal your personal information when answering some of the questions. To minimize 
this, please, feel free to choose not to answer any questions you do not want to. The 
interview will take about 60 minutes of your time. 
Anticipated Benefits 
If you decide to participate in this study, you will receive no direct benefits from answering 
our questions. However, your contribution may help researchers better understand 
challenges you encounter in obtaining informed consent in the RHDGen study. We hope 
that this study will help us to improve the current informed consent process in genomic 
and genetic studies.  
Confidentiality 
We will keep what you have said to us private. You will be assigned a unique identification 
number. We will only refer to the numbers in future and not to your name. The information 
collected will be kept in restricted access offices and on password-secured computers. 
The information will be available to the Student Investigator and Dr Jantina De Vries only. 
The Principal Investigator of the RHDGen study will not have access to your transcript. In 
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addition, we will get your permission to use quotes from you in the thesis and publication. 
The recordings of the interview and transcript will be kept until the end of the study. When 
we report on our findings, we may use some of the sentences that you said. If we use 
one of your sentences, it will appear together with your unique identification number for 
the interview (for instance, IDI #02). We also ask you to keep what we discuss in the 
interview private.  
Voluntariness and the right to withdraw 
Your participation in this study is entirely voluntary, and there are no consequences if you 
decide not to participate. If a question makes you uncomfortable and you don’t want to 
answer it, then feel free to skip it. If during the interview or at a later date you have second 
thoughts, then please feel free to withdraw from the study and if you do we will not 
consider what you said during the interview. Please, feel free to ask the Student 
Investigator any questions you may have about this research study.  
Compensation 
You will not receive any compensation for your participation in this study.  
Contact Information 
If you would like more information about this research study before deciding to participate, 
and if you have questions or comments, please contact Mr. Francis Masiye, at any time 
on the following telephone number; 021 650 1902 and he will answer your questions. You 
can also contact Dr. Jantina de Vries at 021 650 5716 or Prof Bongani Mayosi at 021 406 
6200.If you have concerns about your rights because you think you have not been treated 
fairly or think you have been hurt by joining the study, you can contact the Human 
Research Ethics Committee in the Faculty of Health Sciences at the University of Cape 
Town on 021 406 6338 or write to Shuretta Thomas, Human Research Ethics Committee, 
Room E52 - 24, Old Main Building, Groote Schuur Hospital, OBSERVATORY 7925.  
Signature Page of Consent Form 
Have you been provided with sufficient information about the study? Yes         No  
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Have you had an opportunity to ask questions and discuss this study?  Yes       No 
 
Have you received satisfactory answers to all your questions?            Yes          No 
Do you understand that your participation is voluntary, and that you are free to withdraw 
from the study at any time? 
                                                                                                            Yes           No 
 
Do you agree to take part in this study?                                              Yes           No 
 
Do you agree to be audio-recorded during the interview?              Yes        No 
 
Signature………………………………………………..Date…………………………. 
Name of Study Participant…………………………………………………………….. 
Student Investigator Statement 
I confirm that the study participant has understood the information and voluntarily agreed 
to participate in the study. 
Signature…………………………………………….….Date…………………………. 
Name of Student Investigator…………………………………………………. 
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Appendix III: Information Sheet and Consent Form for RHDGen Research Staff 
Participating in Participant Observations  
 
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina de Vries  
Introduction  
We invite you to participate in a study. This consent form explains the research study you 
are being asked to join. Please, read it carefully and ask any questions about the study 
before you agree to join. You may also ask questions at any time after joining the study. 
If you agree to participate, the Student Investigator will observe your administration of the 
consent procedures of potential research participant in the RHDGen Study and take notes 
during the observation. The observation will be anonymised and nobody except the 
Student Investigator will have access to the notes taken during the consent process 
except in cases when you give your permission to have them used in the thesis and 
publications.  
Purpose of the study 
The purpose of this study is to understand ethical challenges in obtaining informed 
consent for the genomic epidemiological study on rheumatic heart disease you are 
involved in as a Research Staff. We hope to use the findings of this study to explore 
possible interventions for improving ethical challenges in obtaining informed consent in 
genomic research. 
Participants 
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For this study, the Student Investigator hopes to observe administration of the consent 
procedures of adult cases and healthy population controls who will be recruited into the 
RHDGen research project at the Groote Schuur Hospital and in communities within Cape 
Town.  
He will be present at as many consent procedures as possible for both adult cases and 
population controls until he feels that he has developed a clear understanding of the 
dynamics of issues in the consent process. If you agree to participate, he will obtain your 
written consent once before the first participant observation and continue observing the 
rest of the consent procedures of both adult cases and healthy population controls 
recruited into the RHDGen study. During each observation, he will take notes and type 
the notes immediately after the observation. The observation will last at the end of the 
consent procedures. At the end of this study, we would like to keep the typed notes of the 
observation. The notes will be anonymous and nobody will know that it was you who 
administered the consent procedures.  
 
Risks/Discomforts 
There are no physical risks in this study. However, you might feel disturbed or tensed with 
the presence of the Student Investigator during the consent procedures. To minimize this, 
please, feel free to ask the Student Investigator not to observe and take notes during any 
of the consent procedures. 
Anticipated Benefits 
If you decide to participate in this study, you will receive no direct benefits. However, 
observations of the consent procedures may help researchers better understand 
challenges you encounter in obtaining informed consent in the RHDGen study. We hope 
that this study will help us to improve the current informed consent process in genomic 
and genetic studies.  
Confidentiality 
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We will keep the notes taken during the consent procedures private. Each observation 
will be assigned a unique identification number. We will only refer to the observation 
numbers in future. The information collected will be kept in restricted access offices and 
on password-secured computers. The information will be available to the Student 
Investigator. The Principal Investigator of the RHDGen study will not have access to the 
notes. In addition, we will get your permission to the typed notes in the thesis and 
publications. The typed notes of the observations will be kept until the end of the study. 
When we report on our findings, we may highlight some of the issues noted during the 
observations and if we highlight the issues, they will appear together with the observation 
unique identification number (for instance, PO #05).  
Voluntariness and the right to withdraw 
Your participation in this study is entirely voluntary, and there are no consequences if you 
decide not to let the Student Investigator observe any of the consent procedures. If during 
the observation or at a later date you have second thoughts, then please feel free to ask 
the Student Investigator not to use the notes from the observation and if you do he will 
not consider the notes taken during the consent process. Please, feel free to ask the 
Student Investigator any questions you may have about this research study.  
Compensation 
You will not receive any compensation for your participation in this study.  
Contact Information 
If you would like more information about this research project before deciding to 
participate, and if you have questions or comments, please contact Mr Francis Masiye at 
any time and he will answer your questions. You can contact Mr Francis Masiye at the 
following number; 021 650 1902. You can also contact Jantina de Vries at 021 650 5716 
or Bongani Mayosi at 021 406 6200.If you have concerns about your rights because you 
think you have not been treated fairly or think you have been hurt by joining the study, 
you can contact the Human Research Ethics Committee on 021 406 6338 or go to their 
Office in Room E52 - 24  
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Signature Page of Consent Form 
Have you been provided with sufficient information about the study?  Yes        No  
 
Have you had an opportunity to ask questions and discuss this study? Yes      No 
 
Have you received satisfactory answers to all your questions?           Yes         No 
Do you understand that your participation is voluntary, and that you are free to withdraw 
from the study at any time?  
                                                                                                            Yes             No 
 
Do you agree to take part in this study?                                              Yes            No  
 
Signature………………………………………………..Date…………………………. 
Name of Study Participant…………………………………………………………….. 
Student Investigator Statement 
I confirm that the study participant has understood the information and voluntarily agreed 
to participate in the study. 
Signature…………………………………………….….Date…………………………. 
Name of Student Investigator………………………………………… 
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Appendix IV: Information Sheet for RHDGen Adult Cases and Controls 
Participating in Observations  
 
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina de Vries  
Introduction  
We invite you to participate in a study. This information sheet explains the research study 
you are being asked to join. Please, read it carefully and ask any questions about the 
study before you agree to join. You may also ask questions at any time after joining the 
study. If you agree to participate, the Student Investigator will observe your consent 
process into the RHDGen study. The observation will be anonymised and nobody except 
the researchers will know it was you who was being consented into the RHDGen study.  
Purpose of the study 
The purpose of this study is to understand ethical challenges in obtaining informed 
consent for the study on rheumatic heart disease that you are being asked to join. We 
hope to use the findings of this study to explore possible interventions for improving 
ethical challenges in obtaining informed consent in genomic research 
Participants 
For this study, we hope to observe the consent procedures of patients with rheumatic 
heart disease and people who do not have the disease who are being recruited into the 
RHDGen research project at the Groote Schuur Hospital and in communities within Cape 
Town. If you agree to participate, the Student Investigator will be present during the 
consent process and he will write down notes that are relevant for the observation. The 
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notes will be typed immediately after the observation. At the end of this study, we would 
like to keep the typed notes. The notes will be anonymous and nobody will know that it 
was you who was being consented into the RHDGen study. The observation will last at 
the end of the consent process.  
Risks/Discomforts 
There are no physical risks in this study. However, you might feel uncomfortable with the 
presence of the Student Investigator during the consent process. To minimize this, 
please, feel free to choose not to have the Student Investigator observe the consent 
process.  
Anticipated Benefits 
If you decide to participate in this study, you will receive no direct benefits. However, the 
notes taken during the observation may help researchers better understand the 
challenges in obtaining informed consent in the RHDGen study. We hope that this study 
will help us to improve the current consent process for genomic and genetic studies.  
Confidentiality 
We will keep the notes taken during the observation strictly confidential. Each observation 
will be assigned a unique identification number. We will only refer to the observation 
number in our reports. The typed notes will be kept in restricted access offices and on 
password-secured computers. The notes will be kept until the end of the study. When we 
report on our findings, we may highlight some of the issues noted during the observation 
and if we use them they will appear together with the unique identification number for the 
observation (for instance, PO#10).  
Voluntariness and the right to withdraw 
Your participation in this study is entirely voluntary, and there are no consequences if you 
decide not to participate. If you allow the Student Investigator to observe the consent 
process and during the observation or at a later date you have second thoughts, then feel 
free to ask the Student Investigator not to use the notes taken during the consent 
128 
 
procedures. And if you do we will not consider the notes. Please, feel free to ask me any 
questions you may have about this research study.  
 
Compensation 
You will not receive any compensation for participating in the observation.  
Contact Information 
If you would like more information about this research project before deciding to 
participate, please ask the Student Investigator before the beginning of the consent 
process at the following number; 021 650 1902. You can also contact Jantina de Vries at 
021 650 5716 or Bongani Mayosi at 021 406 6200. If you have concerns about your rights 
because you think you have not been treated fairly or think you have been hurt by joining 
the study, you can contact the Human Research Ethics Committee in the Faculty of Health 
Sciences at the University of Cape Town on 021 406 6338 or write to Shuretta Thomas, 
Human Research Ethics Committee, Room E52 - 24, Old Main Building, Groote Schuur 
Hospital, OBSERVATORY 7925.  
Participant Observation Number: ___________________ 
Verbal Consent for the Observation  
Do you agree to take part in this study?                                               Yes           No 
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Appendix V: In-Depth Interview Guide for RHDGen Adult Cases and Controls  
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina De Vries  
1. Knowledge about genetics 
a. What do you understand by the term “genetics”? (Probe: what she/he knows about 
genes, DNA and genetic mutation) 
b. Why are genetic studies conducted? 
2. Knowledge about the RHDGen Study 
a. Please, tell me about the study you joined (Probe: what was the purpose of the 
study or why the study is being conducted) 
b. Can you tell me a little bit about your disease? (Prompt: are participants familiar 
with the term Rheumatic Heart Disease/ Valve Disease) 
c. Please, explain to me the procedures that were followed during your recruitment 
and participation in the study (Probe about the consent procedures and study 
procedures) 
d. How did you feel about being in the study and why? 
3. Understanding of information disclosed during the consent process 
a. Can you remember what the nurse told you about the study? (Probe about the 
types of sample that were being collected and why they were being collected) 
b. Did she say anything about risks or benefits involved? (If yes, what were the risks 
of the study and what were the benefits of the study? 
c. Did she tell you about the study procedures? What did the nurse tell you about 
genetics?  
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d. What did the sharing of your samples and data with other researchers mean to 
you? 
e. What do you think about giving permission for the use of your samples and data in 
future research? 
f. Were you satisfied with the information which was given to you about the study? 
(Probe why or why not? 
g. What things helped you to understand the study? (Probe: Ask her/him to explain 
what could be done to ensure understanding of the information) 
4. Voluntariness of decision to participate in the study 
a. Why did you choose to participate in the study? Or what motivated you to join the 
study? 
b. Did you feel any pressure, from any source, to participate in the study (If so, from 
whom and can you elaborate)? 
c. Did you inform your family about your participation in the study? If yes or no, why? 
d. What problems (if any) did you face during your participation in the study and what 
do you think can be done to minimize such problems? 
5. Suggestions for improving the consent process 
a. What can be done to improve the consent process and the recruitment in this study? 
b. Is there anything that we didn’t discuss that you would like to mention or talk about?  
THANK YOU VERY MUCH FOR YOUR PARTICIPATION!   
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Appendix VI: In-depth Interview Guide for RHDGen Research Staff 
Title of the study: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
Student Investigator: Mr. Francis Masiye 
Supervisors: Prof Bongani Mayosi and Dr. Jantina de Vries  
1. What do you know of the RHDGen study, can you briefly describe it to me?  
2. What are your experiences with seeking IC for this study? (Prompt: particular 
challenges? What do you find difficult?) 
3. How do you explain the concepts of genes, genetics, DNA and data release to 
potential research participants? 
4. Do you link these explanations specifically to participants’ disease? 
5. Do you think potential participants understand the concepts of sample sharing and 
data sharing?  
6. Do people ask you questions about the study? If so, what questions do you get? 
7. Do people refuse and why? 
8. Do you think your role as a Research Nurse affects the decision potential 
participants make to join the RHDGen study or not and why do you think so? 
9. Do you try to ensure that potential participants understand the RHDGen study? 
10. In your opinion, what factors hinder potential participants’ understanding of the 
study? 
11. What information do potential participants find difficult to understand and why do you 
think so? 
12. What aspects of the study do you find difficult to explain to potential study 
participants? 
13. How do you ensure that their decision to participate in the study is voluntary? 
14. Do you face any challenges when you are recruiting patients from the clinic versus 
the Clinical Research Centre? If so, what are the challenges?  
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15. In your opinion, are there any differences between recruiting patients in the hospital 
and recruiting healthy volunteers in the communities? If so, what are the differences 
and where is it easy to recruit potential participants and why? 
16. How best should the consenting process be obtained from potential research 
participants in the RHDGen study? 
 
THANK YOU VERY MUCH FOR YOUR PARTICIPATION! 
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Appendix VII: IDI DEMOGRAPHIC DATA FORM FOR RHDGEN RESEARCH STAFF  
 
TITLE OF STUDY: Ethical Challenges for Obtaining Informed Consent in the 
RHDGen Study 
NAME OF INTERVIEWER: ________________________ 
VENUE/SITE OF INTERVIEW: _____________________  
NAME OF RESPONDENT: __________________________ 
TYPE OF RESPONDENT: ___________________________ 
DATE OF INTERVIEW: ____________________________                  
TIME START: _____________ TIME FINISH: ____________________ 
Subject 
ID No. 
Specific roles in RHDGen Study 
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Appendix VIII: IDI RESPONDENT DEMOGRAPHIC DATA FORM FOR CONTROLS 
AND CASES  
 
TITLE OF STUDY: Ethical Challenges in Obtaining Informed Consent in the RHDGen 
Study 
NAME OF INTERVIEWER: __________________________ 
RHDGEN PARTICIPANT NUMBER: ___________________  
VENUE/SITE OF INTERVIEW: ____________________  
 
TYPE OF RESPONDENT:                 Control               Case 
TIME SINCE RECRUITMENT INTO RHDGEN STUDY: Same Day                        Later             
No. of months_________ 
DATE OF INTERVIEW: __________________  
TIME START: _____________ TIME FINISH: ____________________ 
Subject 
ID No. 
Sex Age Highest 
education 
achieved 
1st 
Language 
Occupation Religion Location/Community 
        
 
 
 
 
